How many Adalimumab clinical trials are there?

463 Adalimumab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 31 are actively recruiting participants. 307 are marked completed.

Are Adalimumab clinical trials recruiting in 2026?

Yes — 31 Adalimumab trials are actively recruiting in 2026, with 66 U.S. sites across 27 states. See the recruiting trials and the per-state site list further down this page.

What conditions is Adalimumab being studied for?

Adalimumab is being studied for Rheumatoid Arthritis, Psoriasis, Crohn's Disease, Ulcerative Colitis, Psoriatic Arthritis and 188 more. The trials are grouped by indication on this page.

What phase is Adalimumab in?

Adalimumab clinical trials span 116 Phase 4, 153 Phase 3, 71 Phase 2, 28 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.

Who sponsors Adalimumab clinical trials?

The lead sponsor across the most Adalimumab trials is Abbott, with 215 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Adalimumab Clinical Trials (2026): 463 Studies for Rheumatoid Arthritis & Psoriasis

Creator: Hipa.ai Research
Published: 2026-05-08T19:11:39.296Z

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: June 18, 2026.

463 Adalimumab clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 120 indications (including Rheumatoid Arthritis & Psoriasis) and 134,928 total planned enrollment. 153 Phase 3 Adalimumab trials and 71 Phase 2, 116 Phase 4 are listed. 49 Adalimumab clinical trials are actively recruiting at 66 U.S. sites across 27 states. Most recent activity: NCT04725422 (Aug 2050).

Where to Participate: All Adalimumab Trial Sites in the U.S. (66 sites across 27 states)

Every actively recruiting Adalimumabtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

State	Facility	City	Trial	Map
AL	Digestive Health Specialsits	Dothan36301	NCT06045754	Map
AZ	GI Alliance Sun City	Sun City85351	NCT06045754	Map
AR	Arkansas Children's Hospital /ID# 258776	Little Rock72202	NCT06100744	Map
CA	University of California San Diego Health (UCSD)	La Jolla92037	NCT06045754	Map
CA	Cedars-Sinai Medical Center	Los Angeles90048	NCT06045754	Map
CA	Hoag Hospital Newport Beach	Newport Beach92663	NCT06045754	Map
CA	UCSF	San Francisco94143	NCT07061574	Map
CT	Medical Research Center of Connecticut, LLC	Hamden06518	NCT06045754	Map
DC	Childrens National Medical Center /ID# 259284	Washington D.C.20010-2916	NCT06100744	Map
FL	University of Florida	Gainesville32610	NCT07061574	Map
FL	Joe Dimaggio Children's Hospital Hollywood /ID# 260634	Hollywood33021	NCT06100744	Map
FL	Clinical Research of Osceola	Kissimmee34741	NCT06045754	Map
FL	University of Miami	Miami33136	NCT07061574	Map
FL	Endoscopic Research Inc	Orlando32803	NCT06045754	Map
FL	Alliance Clinical Research of Tampa, LLC	Tampa33615	NCT06045754	Map
GA	Gastroenterology Consultants, P.C.	Roswell30076	NCT06045754	Map
IL	University of Chicago Medicine	Chicago60637	NCT06045754	Map
IL	GI Alliance - Illinois Gastroenterology Group - Glenview	Glenview60026	NCT06045754	Map
IL	NorthShore University HealthSystem	Glenview60026	NCT06062875	Map
IL	GI Alliance - Illinois Gastroenterology Group LLC - Gurnee	Gurnee60031	NCT06045754	Map
IN	Indiana University	Indianapolis46202	NCT07061574	Map
IN	Indiana University Health Riley Hospital for Children /ID# 259067	Indianapolis46202	NCT06100744	Map
KS	University of Kansas Medical Center	Kansas City66160	NCT06045754	Map
KS	Cotton ONeil Clinical Research Center	Topeka66606	NCT06045754	Map
KY	University of Louisville	Louisville40202	NCT06045754	Map
LA	GI Alliance	Metairie70006	NCT06045754	Map
LA	Tulane University	New Orleans70112	NCT06045754	Map
MI	Huron Gastroenterology Associates, P.C.	Ypsilanti48197	NCT06045754	Map
MN	M Health Fairview University of Minnesota Medical Center - West Bank /ID# 260111	Minneapolis55454	NCT06100744	Map
MN	University of Minnesota	Minneapolis55455	NCT07061574	Map
MO	Mid-America Gastro-Intestinal Consultants	Kansas City64111	NCT06045754	Map
MO	BVL Clinical Research	Liberty64068	NCT06045754	Map
MO	Washington University School of Medicine	St Louis63110	NCT06045754	Map
NE	University of Nebraska Medical Center	Omaha68198	NCT03414502	Map
NY	University of Buffalo	Buffalo14203	NCT07061574	Map
NY	Columbia University Medical Center /ID# 262587	New York10032-3729	NCT06100744	Map
NY	NYU Langone Health	New York10016	NCT06045754	Map
NY	Boston Childrens Health Physicians /ID# 258061	Valhalla10595	NCT06100744	Map
NC	University of North Carolina - Children's Hospital /ID# 259286	Chapel Hill27514	NCT06100744	Map
OH	University of Cincinnati	Cincinnati45627	NCT06045754	Map
OH	MetroHealth Medical Center /ID# 262377	Cleveland44109	NCT06100744	Map
OH	Ohio Gastroenterology group, Inc.	Columbus43202	NCT06045754	Map
OH	Great Lakes Gastroenterology Research, LLC	Mentor44060	NCT06045754	Map
OH	Gastro Intestinal Research Institute of Northern Ohio, LLC.	Westlake44145	NCT06045754	Map
OK	Digestive Disease Specialists, Inc.	Oklahoma City73114	NCT06045754	Map
PA	University of Pennsylvania	Philadelphia19104	NCT06941376	Map
PA	University of Pittsburgh	Pittsburgh15224	NCT07061574	Map
PA	Allegheny Health Network	Wexford15090	NCT06045754	Map
RI	University Gastroenterology	Providence02905	NCT06045754	Map
SD	Rapid City Medical Center, LLP	Rapid City57701	NCT06045754	Map
TX	Child Neurology Consultants of Austin /ID# 260562	Austin78757-7571	NCT06100744	Map
TX	Texas Digestive Disease Consultants Cedar Park	Cedar Park78613	NCT06045754	Map
TX	GI Alliance - Digestive Health Associates of Texas	Dallas75044	NCT06045754	Map
TX	Baylor College of Medicine	Houston77030	NCT07061574	Map
TX	The University of Texas Health Science Center at Houston	Houston77030	NCT06045754	Map
TX	Texas Digestive Disease Consultants Lubbock	Lubbock79410	NCT06045754	Map
TX	GI Alliance - Mansfield	Mansfield76063	NCT06045754	Map
TX	Gastroenterology Research of San Antonio, LLC	San Antonio78229	NCT06045754	Map
TX	Southern Star Research Institute, LLC.	San Antonio78229	NCT06045754	Map
TX	Texas Digestive Disease Consultants (TDDC), Southlake	Southlake76092	NCT06045754	Map
TX	Tyler Research Institute, LLC	Tyler75701	NCT06045754	Map
TX	GI Alliance - Webster	Webster77598	NCT06045754	Map
UT	University of Utah Health	Salt Lake City84108	NCT06045754	Map
WA	Seattle Children's Hospital	Seattle98105	NCT04725422	Map
WA	Seattle Children's Hospital	Seattle98105	NCT07061574	Map
WA	Washington Gastroenterology- GIA	Tacoma98405	NCT06045754	Map

Adalimumab clinical trials at a glance: phase × recruitment status

Phase	recruiting	active not recruiting	enrolling by invitation	completed	terminated	withdrawn	not yet recruiting	unknown	approved for marketing	Total
Early P1				1			1			2
P1	1			24		1	1	1		28
P1/P2	1	2		4		1	1	1		10
P2	9	1		41	7	6	4	3		71
P2/P3		1		8				3		12
P3	2	7		125	5	4	1	9		153
P4	12		1	60	9	3	7	24		116
N/A	5	2		44	3	2	3	9	3	71

Recruiting Adalimumab clinical trials (49)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT ID	Title	Phase	Indication	Enrollment	Started
NCT04725422	CHOIRCHronic Nonbacterial Osteomyelitis International Registry	—	Chronic Nonbacterial Osteomyelitis	2,000	Aug 2018
NCT01706692	SDNTTSwiss Dermatology Network of Targeted Therapies (SDNTT)	—	Psoriasis	1,121	Feb 2011
NCT07061574	WAVE T1DA Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes	P1/P2	Type 1 Diabetes	120	Mar 2026
NCT07352566	Utilization of a Microdevice for Psoriasis and Atopic Dermatitis	P4	Psoriasis	10	Aug 2026
NCT07268534	BOOSTERSBiologics in Folliculitis Decalvans : an Adaptative Trial Research	P2	Folliculitis Decalvans (FD)	120	Apr 2026
NCT07510191	CDTNFi Plus Low-Dose Upadacitinib vs TNFi Intensification in Crohn's Disease With Suboptimal Response	P4	Crohn Disease (CD)	312	Mar 2026
NCT06996652	PRISMSAn Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)	P2	REM Sleep Behavior Disorder	108	Jun 2026
NCT06390436	SMOOTHTherapeutic Drug Monitoring-baSed adalimuMab De-escalatiOn in nOn-infecTious cHronic Uveitis	P4	Uveitis	320	Jun 2025
NCT07564505	Post - Marketing Case Registration Study on the Safety and Efficacy of Adalimumab Solution for Injection in Chinese Pediatric Patients With Moderate - to - Severe Active Crohn's Disease	P4	Children Aged 6 Years and Above With Moderate - to - Severe Active Crohn's Disease	30	May 2026
NCT03414502	Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response	P3	Rheumatoid Arthritis	400	Dec 2007
NCT07423533	Phase IIb Clinical Study to Assess the Efficacy and Safety of GenSci120 Injection in Patients With Moderately to Severely Active RA Who Have an Inadequate Response to at Least One DMARD	P2	Rheumatoid Arthritis	450	Apr 2026
NCT06037811	Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis	P2	Inflammatory Arthritis	30	Apr 2024
NCT05928039	PATHFINDERPATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease	P4	Crohn Disease	297	Oct 2023
NCT06016517	Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis	—	Arthritis, Rheumatoid	18	May 2026
NCT06180382	VEDIANComparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration.	P4	Crohn's Disease	220	Oct 2024
NCT06100744	A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab	P3	Juvenile Psoriatic Arthritis	40	Jul 2024
NCT06849908	Baricitinib in the Treatment of Intestinal Behçet's Syndrome	P2	Behcet Syndrome, Intestinal Type	56	Nov 2024
NCT06926478	Subconjunctival Humira for Boston Keratoprosthesis	P1	Penetrating Keratoplasty	8	Jun 2026
NCT06062875	Effects of TNF Blockade on Human BPH/LUTS	P2	Benign Prostatic Hyperplasia (BPH)	70	Jan 2024
NCT07529925	A Clinical Trail of Adalimumab in Treating Chinese Children With Severe Plaque Psoriasis	P4	Severe Plaque Psoriasis in Chinese Children	30	May 2026
NCT04183608	CONTROLA Trial COmparing staNdard of Care Versus Treat to Target With telemonitoRing and Patient Education in Patients With Ulcerative cOlitis Initiating Adalimumab	P4	Ulcerative Colitis	238	Jan 2020
NCT07258641	VOYAGERFluorescence Imaging of Adalimumab-680LT and Risankizumab-800CW in Inflammatory Bowel Disease	P1/P2	Ulcerative Colitis (UC)	30	Jan 2026
NCT07013838	The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis	P4	Takayasu Arteritis (TAK)	50	Jun 2025
NCT06833112	IL-17Interleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor for the Treatment of Ankylosing Spondylitis	P4	Ankylosing Spondylitis	10	Feb 2025
NCT06941376	PROSECT RPAn Open-Label Study of Effectiveness of Immunomodulatory Medications for Patients With Relapsing Polychondritis	P2	Relapsing Polychondritis	20	Aug 2025
NCT06440629	RA-DRUMEffect of Proactive Therapeutic Drug Monitoring on Maintenance of Sustained Disease Control in Adults With Rheumatoid Arthritis on a Subcutaneous TNF Inhibitor: The Rheumatoid Arthritis Therapeutic DRUg Monitoring Trial (RA-DRUM)	P4	Rheumatoid Arthritis	350	Aug 2024
NCT05590455	TIMPANITnf Inhibitors to Reduce Mortality in HIV-1 Infected PAtients With Tuberculosis meNIngitis	P2	Tuberculous Meningitis	130	Apr 2023
NCT05503875	Immunoclassification of Psoriasis: a Strategy for Precision Medicine	N/A	Immunoclassification	100	Jan 2023
NCT07491913	Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission	N/A	Takayasu Arteritis	40	Jun 2025
NCT07151937	A Study of LAD191 in Adults With Hidradenitis Suppurativa	P2	Hidradenitis Suppurativa	200	Nov 2025
NCT06258915	FOCUSTreatment FOr Corticosteroid Dependent UveitiS	P3	Non Infectious Uveitis	120	Mar 2024
NCT07138898	Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty	P2	Rheumatic Disease	80	Sep 2025
NCT05874505	UVB"Comparison of the Efficacy and Safety of Adalimumab to That of Tocilizumab in Severe Uveitis of Behçet's Disease"	P2	Behcet's Uveitis	60	Jul 2023
NCT07495644	Efficacy of Different Biological Treatments in Patients With Inflammatory Bowel Disease After One Year of Treatment in Upper Egypt	—	Inflamatory Bowel Disease (Crohn's and Ulcerative Colitis)	95	Mar 2026
NCT06498089	A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis	P4	Takayasu Arteritis	124	Jun 2024
NCT06045754	IVA Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease	P4	Crohn's Disease	100	Apr 2024
NCT05626348	The Clinical Efficacy of Immunomodulators in RA Patients	P4	Arthritis, Rheumatoid	400	Dec 2021
NCT05105347	Efficacy and Safety of Adalimumab Plus Medium Dose Oral Glucocorticosteroid for Refractory Behçet's Uveitis	P4	Uveitis	130	Nov 2021
NCT07398651	Apremilast and Adalimumab in Psoriatic Arthritis Patients	N/A	Psoriatic Arthritis	60	Dec 2026
NCT06742606	Efficacy of Biological Therapy in Pediatric Inflammatory Bowel Disease	Early P1	Effect of Drug	40	Jan 2025
NCT03917303	CoCroSControl Crohn Safe Trial	P4	Crohn Disease	158	Dec 2019
NCT03938701	STRATIFYFluorescence Imaging of IBD and RA Using Adalimumab-800CW	P2	IBD	36	Aug 2024
NCT04646187	FREEDe-escalation of Anti-TNF Therapy in Inflammatory Bowel Disease	P4	Inflammatory Bowel Diseases	148	Mar 2021
NCT02706704	IVASIntravitreal Adalimumab Versus Subcutaneous Adalimumab in Non-infectious Uveitis	P2	Uveitis	32	Feb 2016
NCT05313620	Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events	P4	Ulcerative Colitis	30	Apr 2022
NCT07181694	A Study of Pharmacokinetics, Safety, and Immunogenicity of BCD-057 100 mg/mL, BCD-057 50 mg/mL, and Humira 100 mg/mL in Healthy Subjects	P1	Healthy Adult Male	444	Mar 2025
NCT06527534	FILRAFilgotinib Effect on Proteomic Profile and Micro-RNA Expression in Patients With Active Rheumatoid Arthritis (RA)	P4	Rheumatoid Arthritis	30	Jul 2024
NCT05590416	A Study of Adalimumab in Acute Vogt-Koyanagi-Harada Disease	—	Vogt-Koyanagi-Harada Disease	15	Jun 2021
NCT04300686	A Pilot Study in Severe Patients With Takayasu Arteritis.	P4	Takayasu Arteritis	40	Mar 2020

Adalimumab clinical trials by indication

Rheumatoid Arthritis (110)

NCT	Acronym	Phase	Status	Title
NCT03414502	—	P3	recruiting	Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
NCT07423533	—	P2	recruiting	Phase IIb Clinical Study to Assess the Efficacy and Safety of GenSci120 Injection in Patients With Moderately to Severely Active RA Who Have an Inadequate Response to at Least One DMARD
NCT06440629	RA-DRUM	P4	recruiting	Effect of Proactive Therapeutic Drug Monitoring on Maintenance of Sustained Disease Control in Adults With Rheumatoid Arthritis on a Subcutaneous TNF Inhibitor: The Rheumatoid Arthritis Therapeutic DRUg Monitoring Trial (RA-DRUM)
NCT02629159	SELECT-COMPARE	P3	active not recruiting	A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
NCT04909801	—	P3	active not recruiting	A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate
NCT05814627	SELECT- SWITCH	P3	active not recruiting	Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
NCT05502731	JAKAR	P4	unknown	Januse Kinase Inhibition With Filgotinib to Silence Autoreactive B Cells in Rheumatoid Arthritis
NCT06527534	FILRA	P4	recruiting	Filgotinib Effect on Proteomic Profile and Micro-RNA Expression in Patients With Active Rheumatoid Arthritis (RA)
+ 102 more, see All trials below.

Psoriasis (40)

NCT	Acronym	Phase	Status	Title
NCT01706692	SDNTT	N/A	recruiting	Swiss Dermatology Network of Targeted Therapies (SDNTT)
NCT07352566	—	P4	not yet recruiting	Utilization of a Microdevice for Psoriasis and Atopic Dermatitis
NCT03927352	—	P3	unknown	The Purpose of This Research Study is to Compare the Efficacy and Safety of SCT630 and Adalimumab (HUMIRA®) in Adults With Plaque Psoriasis
NCT05683054	—	P4	completed	A Non-inferiority Study on Dose Reduction of Adalimumab in Psoriasis Patients Who Are Overtreated
NCT04808739	—	N/A	completed	Adalimumab Biosimilar in Clinical Practice
NCT02207244	VOYAGE 2	P3	completed	A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment
NCT02207231	VOYAGE 1	P3	completed	A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis
NCT03217734	MAP	P2/P3	completed	MAP Study: Methotrexate and Adalimumab in Psoriasis
+ 32 more, see All trials below.

Crohn's Disease (36)

NCT	Acronym	Phase	Status	Title
NCT06180382	VEDIAN	P4	recruiting	Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration.
NCT06045754	IV	P4	recruiting	A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
NCT04643483	—	P3	withdrawn	A Study to Test Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Crohn's Disease
NCT04131504	ENvISION	N/A	completed	Precision Crohn's Disease Management Utilizing Predictive Protein Panels (ENvISION)
NCT02994836	—	P4	completed	GIS-SUSANTI-TNF-2015 (Anti-TNF Discontinuation )
NCT02852694	RCT	P4	completed	Reduce Risk for Crohn's Disease Patients
NCT02065570	—	P3	completed	Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease
NCT02256462	PAILOT	P4	completed	Pediatric Crohn's Disease AdalImumab Level-based Optimization Treatment (PAILOT) Trial
+ 28 more, see All trials below.

Ulcerative Colitis (20)

NCT	Acronym	Phase	Status	Title
NCT04183608	CONTROL	P4	recruiting	A Trial COmparing staNdard of Care Versus Treat to Target With telemonitoRing and Patient Education in Patients With Ulcerative cOlitis Initiating Adalimumab
NCT06257875	IV	P2	active not recruiting	A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis
NCT05313620	—	P4	recruiting	Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events
NCT02632175	—	P3	completed	Long-term Safety and Efficacy Study of Adalimumab in Pediatric Subjects With Ulcerative Colitis
NCT06269185	—	N/A	completed	Comparison Between Infliximab and Adalimumab on Patients With Ulcerative Colitis
NCT04882683	—	N/A	unknown	Clinical Study of Cord Blood Mononuclear Cells on Treatment of Hormone-resistant or Hormone-dependent Ulcerative Colitis
NCT05530122	biological	N/A	completed	Prognosis in UC After First Biological
NCT05372939	MARKET	P2	completed	Study of the Efficacy and Safety of AMT-101 in Combination With Adalimumab in Subjects With Ulcerative Colitis (MARKET)
+ 12 more, see All trials below.

Psoriatic Arthritis (19)

NCT	Acronym	Phase	Status	Title
NCT07398651	—	N/A	not yet recruiting	Apremilast and Adalimumab in Psoriatic Arthritis Patients
NCT04610476	—	P3	unknown	Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis
NCT03739853	SPEED	P4	completed	Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED Trial
NCT03104400	SELECT - PsA 1	P3	completed	A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)
NCT06600009	FLYWAY	N/A	completed	Treatment Persistence of Biologics in Patients with PsA in Japan; Retrospective Cohort Study Using a Claims Database
NCT03895203	BE OPTIMAL	P3	completed	A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
NCT03955861	—	N/A	completed	Ultrasound Enthesitis Response in Psoriatic Arthritis
NCT04115748	PENGUIN 1	P3	terminated	Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy
+ 11 more, see All trials below.

Uveitis (18)

NCT	Acronym	Phase	Status	Title
NCT06390436	SMOOTH	P4	not yet recruiting	Therapeutic Drug Monitoring-baSed adalimuMab De-escalatiOn in nOn-infecTious cHronic Uveitis
NCT04088409	LY3009104	P3	active not recruiting	A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis
NCT05105347	—	P4	not yet recruiting	Efficacy and Safety of Adalimumab Plus Medium Dose Oral Glucocorticosteroid for Refractory Behçet's Uveitis
NCT06310837	—	N/A	active not recruiting	Effect of Immunosuppressants With Adalimumab Biosimilars vs Corticosteroids on Noninfectious Uveitis
NCT02706704	IVAS	P2	recruiting	Intravitreal Adalimumab Versus Subcutaneous Adalimumab in Non-infectious Uveitis
NCT04798755	Co-THEIA	P3	unknown	Efficacy, Safety and Costs of Methotrexate, Adalimumab, or Their Combination in Non-infectious Non-anterior Uveitis
NCT03816397	ADJUST	P4	completed	Adalimumab in JIA-associated Uveitis Stopping Trial
NCT03828019	ADVISE	P3	completed	Adalimumab vs. Conventional Immunosuppression for Uveitis Trial
+ 10 more, see All trials below.

Ankylosing Spondylitis (15)

NCT	Acronym	Phase	Status	Title
NCT06833112	IL-17	P4	not yet recruiting	Interleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor for the Treatment of Ankylosing Spondylitis
NCT06242652	AS	P2	unknown	A Study to Evaluate 608 in Patients with Ankylosing Spondylitis (AS)
NCT05527444	—	P4	unknown	The Clinical Efficacy and the Changes of Immune Cells Subsets With Bioagents in Ankylosing Spondylitis Patients
NCT05164198	RECAST	P4	unknown	REduCed Dose of TNFi in Patients With Ankylosing SpondyliTis (RECAST)
NCT03259074	SURPASS	P3	completed	Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar)
NCT02492217	TNF	P4	completed	Biomarkers Identification of Anti-tumor Necrosis Factor (TNF) α Agent's Efficacy in Ankylosing Spondylitis Patients
NCT02333383	AS PMOS	N/A	completed	Observe the Frequency of Extra-Axial Symptoms in Korean Ankylosing Spondylitis (AS) Patients
NCT02489760	—	P4	unknown	Etanercept Versus Adalimumab in the Treatment of Patients With Ankylosing Spondylitis. A Switch Study
+ 7 more, see All trials below.

Crohn Disease (14)

NCT	Acronym	Phase	Status	Title
NCT05928039	PATHFINDER	P4	recruiting	PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease
NCT03917303	CoCroS	P4	recruiting	Control Crohn Safe Trial
NCT05913817	EASE PAIN	N/A	completed	The Evaluation of Injection Site Pain and Adherence in Patients Switching From a Low To High Concentration Adalimumab (AVT-02) Across Multiple Indications.
NCT06117423	GUIDE	P1/P2	unknown	Fluorescence Imaging of Adalimumab-680LT in Inflammatory Bowel Disease
NCT03261102	—	N/A	active not recruiting	TDM Guided Early Optimization of ADAL in Crohn's Disease
NCT02332356	—	P3	unknown	Therapeutic Optimization Study Based on MR Enterocolonography in Patients With Crohn's Disease
NCT04655807	DUET	P2	withdrawn	A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease
NCT02764762	CD	P4	completed	Triple Combination Therapy in High Risk Crohn's Disease (CD)
+ 6 more, see All trials below.

Arthritis, Rheumatoid (13)

NCT	Acronym	Phase	Status	Title
NCT06016517	—	N/A	not yet recruiting	Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis
NCT05626348	—	P4	recruiting	The Clinical Efficacy of Immunomodulators in RA Patients
NCT03662919	PERFUSE	N/A	completed	One-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi: a French Cohort Study
NCT02374021	TARGET	P4	completed	Treatments Against RA and Effect on FDG-PET/CT
NCT02092467	TNF	P4	completed	Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis
NCT03254810	—	P1	completed	Comparison of the Safety and PK of SYN060 to Humira® in Healthy Adult Subjects
NCT01197144	PARADE	N/A	completed	Pain Modulation in Rheumatoid Arthritis (RA) - Influence of Adalimumab
NCT02019472	SIRROUND-H	P3	completed	A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis
+ 5 more, see All trials below.

Plaque Psoriasis (13)

NCT	Acronym	Phase	Status	Title
NCT06640517	PLANETA-KIDS	P3	active not recruiting	Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Netakimab in Children With Moderate to Severe Plaque Psoriasis
NCT06005532	—	P3	unknown	Study Evaluation of the Efficacy, Safety and Immunogenicity of Adalimumab in Comparison With Humira®
NCT06370156	—	N/A	unknown	Evaluation of TWEAK in Plaque Psoriasis and Psoriatic Arthritis Patients
NCT05510063	—	P4	completed	Pharmacokinetics, Efficacy, Safety, and Immunogenicity of SB5 Versus Humira in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT05073315	—	P3	completed	A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis
NCT04453137	—	P3	completed	Pharmacokinetic, Efficacy, Safety, and Immunogenicity of AVT02 With Moderate to Severe Chronic Plaque Psoriasis
NCT03849404	—	P3	completed	Efficacy, Safety, and Immunogenicity of AVT02 With Moderate-to-Severe Chronic Plaque Psoriasis
NCT03316781	—	P3	completed	Study of Efficacy and Safety of HLX03 in Subjects With Moderate to Severe Plaque Psoriasis
+ 5 more, see All trials below.

Hidradenitis Suppurativa (11)

NCT	Acronym	Phase	Status	Title
NCT07151937	—	P2	recruiting	A Study of LAD191 in Adults With Hidradenitis Suppurativa
NCT05322473	—	P2	completed	Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa
NCT04988308	LYRA	P2	terminated	A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa
NCT04132388	—	P4	withdrawn	Hidradenitis Suppurativa Patient Experience With Humira Treatment
NCT03221621	HS-COST	P4	unknown	Cost-effectiveness of Adalimumab and Surgery vs Adalimumab in HS
NCT02904902	—	P3	completed	Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa
NCT03248531	—	P2	completed	A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa.
NCT02739828	HOPE	N/A	completed	Post Marketing Observational Study (PMOS) to Assess Quality of Life in Swedish Hidradenitis Suppurativa (HS) Patients
+ 3 more, see All trials below.

Healthy (8)

NCT	Acronym	Phase	Status	Title
NCT05884242	—	P1	completed	A Study of Adalimumab on Inflammatory Mediators Following a Systemic Endotoxin Challenge
NCT04514796	—	P1	completed	Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Two Formulations of SB5 in Healthy Male Subjects
NCT03917628	—	P1	completed	Pharmacokinetics and Safety in Healthy Volunteers
NCT02912247	—	P1	completed	Comparative Clinical Trial to Evaluate Bioequivalency and Safety of Monoclonal Antibody Injection and Adalimumab in Chinese Healthy Volunteers
NCT02395055	—	P1	completed	Comparative Clinical Study of Pharmacokinetics, Tolerance and Safety of BCD-057 and Humira in Healthy Volunteers
NCT02045979	—	P1	completed	Pharmacokinetics and Safety in Healthy Volunteers
NCT01870986	REFLECTIONS B538-01	P1	completed	Study Of PF-06410293 And Adalimumab In Healthy Subjects (REFLECTIONS B538-01)
NCT01505491	—	P1	completed	Pharmacokinetics and Safety Study of BI 695501 in Healthy Subjects

Inflammatory Bowel Diseases (7)

NCT	Acronym	Phase	Status	Title
NCT04646187	FREE	P4	enrolling by invitation	De-escalation of Anti-TNF Therapy in Inflammatory Bowel Disease
NCT03885713	BioIBD	P4	completed	Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease
NCT06033469	—	N/A	unknown	Therapeutic Monitoring of Infliximab and Adalimumab
NCT05291039	—	N/A	completed	Infliximab and Adalimumab in Inflammatory Bowel Disease Patients.
NCT05706038	COV-ADA	N/A	completed	Impact of Adalimumab Withdrawal or Continuation on Severity of COVID-19 and Risk of IMID Relapse
NCT04404517	IntnsificADA	P3	unknown	Correlation of Serum Adalimumab Levels at an Administration of 40 mg Weekly vs 80 mg Every Two Weeks
NCT01971970	IBD	N/A	completed	Biomarkers of Anti-TNF Treatment in Inflammatory Bowel Disease (IBD)

Spondyloarthritis (6)

NCT	Acronym	Phase	Status	Title
NCT01610947	SPACING	N/A	completed	Effect of Spacing of Anti-TNF Drugs in Ankylosing Spondylitis With Low Disease Activity
NCT02696785	COAST-V	P3	completed	A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis
NCT01174186	INTASAH	P4	completed	Intestinal Inflammation in Ankylosing Spondylitis and the Effects of Adalimumab on Mucosal Healing
NCT01029847	ASIM	P4	completed	Adalimumab in Axial Spondyloarthritis (ASIM) - MRI and Biomarkers in Patients With Spondyloarthritis
NCT00477893	DANISH	P4	unknown	Danish Multicenter Study of Adalimumab in Spondyloarthritis
NCT00972218	—	P4	withdrawn	Effectiveness and Safety of Spondylitis Related to Inflammatory Bowel Disease

Axial Spondyloarthritis (5)

NCT	Acronym	Phase	Status	Title
NCT06333210	LEVENTA	P3	active not recruiting	Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of BCD-180 in Patients With Axial Spondyloarthritis (LEVENTA)
NCT03906136	AScalate	P3	completed	AScalate: Treat-to-target in Axial Spondyloarthritis
NCT02897115	STRIKE	P4	terminated	A Study Treating Participants With Early Axial Spondyloarthritis (axSpA) Taking an Intense Treatment Approach Versus Routine Treatment
NCT01808118	—	P3	completed	Continuing Versus Withdrawing Adalimumab in Maintaining Remission in Non-Radiographic Axial Spondyloarthritis
NCT00939003	—	P3	completed	Study of Adalimumab in Patients With Axial Spondyloarthritis

Takayasu Arteritis (4)

NCT	Acronym	Phase	Status	Title
NCT07491913	—	N/A	recruiting	Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission
NCT06498089	—	P4	recruiting	A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis
NCT05151848	ADATOFTAK	P4	unknown	Comparison of Adalimumab and Tofacitinib in the Treatment of Active Takayasu Arteritis
NCT04300686	—	P4	recruiting	A Pilot Study in Severe Patients With Takayasu Arteritis.

Healthy Volunteers (3)

NCT	Acronym	Phase	Status	Title
NCT03849313	—	P1	completed	Pharmacokinetics, Safety and Tolerability Study of AVT02 to EU-approved and US-licensed Humira (Adalimumab)
NCT03579823	ALVOPAD	P1	completed	Comparative Safety, Tolerability, Pharmacokinetic Study of AVT02 (100MG/ML) and Humira (100MG/ML) in Healthy Volunteers
NCT05995691	PK	P1	completed	Study to Determine the Pharmacokinetic (PK) Bioequivalence of ABP 501 and Adalimumab (Humira®) in Healthy Adult Japanese Participants

Juvenile Idiopathic Arthritis (3)

NCT	Acronym	Phase	Status	Title
NCT00783510	STRIVE	N/A	completed	Juvenile Idiopathic Arthritis (JIA) Registry
NCT02840175	AJIBIOREM	P3	completed	Treatment Tapering in JIA With Inactive Disease
NCT00775437	JIA	P3	completed	Active Juvenile Idiopathic Arthritis (JIA) Compassionate Use

Hidradenitis Suppurativa (HS) (3)

NCT	Acronym	Phase	Status	Title
NCT02808975	SHARPS	P4	completed	Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically
NCT01468233	PIONEER II	P3	completed	Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa
NCT01468207	PIONEER I	P3	completed	Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa

Sarcoidosis (3)

NCT	Acronym	Phase	Status	Title
NCT00274352	—	P2	completed	A Study of Adalimumab to Treat Sarcoidosis of the Skin
NCT00311246	—	P2	terminated	Trial of Adalimumab in Progressive Sarcoidosis
NCT00690911	—	P2	withdrawn	Study to Determine the Efficacy of Adalimumab in the Treatment of Cutaneous Sarcoidosis

Ulcerative Colitis (UC) (2)

NCT	Acronym	Phase	Status	Title
NCT07258641	VOYAGER	P1/P2	not yet recruiting	Fluorescence Imaging of Adalimumab-680LT and Risankizumab-800CW in Inflammatory Bowel Disease
NCT02065622	—	P3	completed	Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis

Juvenile Psoriatic Arthritis (2)

NCT	Acronym	Phase	Status	Title
NCT06100744	—	P3	recruiting	A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
NCT04527380	LY2439821	P3	active not recruiting	A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

Pharmacokinetics (2)

NCT	Acronym	Phase	Status	Title
NCT06291948	—	P1	completed	A Clinical Study With Adalimumab Biosimilar
NCT05172817	ACT	P2/P3	unknown	Study to Compare PK & Safety of Advixa With Humira in Healthy, Adult Subject Followed by Efficacy & Safety Study in RA Patients

Rheumatoid Arthritis (RA) (2)

NCT	Acronym	Phase	Status	Title
NCT03823391	RA	P2	completed	A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Participants With Moderate to Severe Rheumatoid Arthritis (RA)
NCT03737708	RA	P4	completed	A Study Comparing Biologics + Methotrexate With Biologics + Tacrolimus in Patients With Rheumatoid Arthritis (RA)

Spondylitis, Ankylosing (2)

NCT	Acronym	Phase	Status	Title
NCT03561649	PRESHUM	N/A	completed	Prediction of Treatment Response at 6 Months by Combinatorial Analysis of Serum Biomarkers in Biotherapy Naive SpA
NCT01870284	SPIRIT A1	P3	withdrawn	Study of Ixekizumab in Participants With Active Ankylosing Spondylitis (AS)

Chronic Plaque Psoriasis (2)

NCT	Acronym	Phase	Status	Title
NCT03412747	BE SURE	P3	completed	A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00574249	BELIEVE	P3	completed	Adalimumab in Combination With Topical Treatment (Calcipotriol/Betamethasone) in Subjects With Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic Treatment

Pyoderma Gangrenosum (2)

NCT	Acronym	Phase	Status	Title
NCT03311464	—	P3	completed	A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in Japan
NCT00690846	—	P2	withdrawn	Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum

RheumatoId Arthritis (2)

NCT	Acronym	Phase	Status	Title
NCT02035800	BROCAII	P4	unknown	Bone Resorption, Osteoclastogenesis and Adalimumab
NCT03016260	RABIOPRED	N/A	terminated	RABIOPRED - a Validation Study of Theranostic Test to PREDict Treatment Response of Anti-TNFα BIologicals in Rheumatoid Arthritis

Inflammatory Bowel Disease (2)

NCT	Acronym	Phase	Status	Title
NCT03043677	—	N/A	completed	Ex-vivo Modulatory Effect of Biological Drugs for Inflammatory Bowel Disease on the Mucosa and on Peripheral Blood Mononuclear Cells
NCT02073526	—	N/A	completed	Anti-TNF-alpha Trough Level Measurements in Inflammatory Bowel Disease

Early Rheumatoid Arthritis (2)

NCT	Acronym	Phase	Status	Title
NCT01185301	CONCERTO	P3	completed	Study to Determine the Effects of Different Doses of Methotrexate (MTX) When Taken With Adalimumab in Subjects With Early Rheumatoid Arthritis (RA)
NCT00195663	PREMIER	P3	completed	Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis

Osteoarthritis (2)

NCT	Acronym	Phase	Status	Title
NCT00686439	—	P1/P2	completed	Adalimumab for Inflammatory Osteoarthritis
NCT00185562	—	P2	completed	A Pilot Trial of Adalimumab for the Treatment of Osteoarthritis

Arthritis (2)

NCT	Acronym	Phase	Status	Title
NCT00646178	—	P3	completed	Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severely Active Psoriatic Arthritis Subjects With Inadequate Response to Disease Modifying Anti-Rheumatic Drug Therapy
NCT00646386	—	P2	completed	Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderately to Severely Active Psoriatic Arthritis

Penetrating Keratoplasty (1)

NCT	Acronym	Phase	Status	Title
NCT06926478	—	P1	not yet recruiting	Subconjunctival Humira for Boston Keratoprosthesis

Severe Plaque Psoriasis in Chinese Children (1)

NCT	Acronym	Phase	Status	Title
NCT07529925	—	P4	not yet recruiting	A Clinical Trail of Adalimumab in Treating Chinese Children With Severe Plaque Psoriasis

REM Sleep Behavior Disorder (1)

NCT	Acronym	Phase	Status	Title
NCT06996652	PRISMS	P2	not yet recruiting	An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)

Children Aged 6 Years and Above With Moderate - to - Severe Active Crohn's Disease (1)

NCT	Acronym	Phase	Status	Title
NCT07564505	—	P4	not yet recruiting	Post - Marketing Case Registration Study on the Safety and Efficacy of Adalimumab Solution for Injection in Chinese Pediatric Patients With Moderate - to - Severe Active Crohn's Disease

Folliculitis Decalvans (FD) (1)

NCT	Acronym	Phase	Status	Title
NCT07268534	BOOSTERS	P2	not yet recruiting	Biologics in Folliculitis Decalvans : an Adaptative Trial Research

Type 1 Diabetes (1)

NCT	Acronym	Phase	Status	Title
NCT07061574	WAVE T1D	P1/P2	recruiting	A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes

Crohn Disease (CD) (1)

NCT	Acronym	Phase	Status	Title
NCT07510191	CD	P4	recruiting	TNFi Plus Low-Dose Upadacitinib vs TNFi Intensification in Crohn's Disease With Suboptimal Response

Inflamatory Bowel Disease (Crohn's and Ulcerative Colitis) (1)

NCT	Acronym	Phase	Status	Title
NCT07495644	—	N/A	not yet recruiting	Efficacy of Different Biological Treatments in Patients With Inflammatory Bowel Disease After One Year of Treatment in Upper Egypt

Rheumatic Disease (1)

NCT	Acronym	Phase	Status	Title
NCT07138898	—	P2	not yet recruiting	Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

Relapsing Polychondritis (1)

NCT	Acronym	Phase	Status	Title
NCT06941376	PROSECT RP	P2	recruiting	An Open-Label Study of Effectiveness of Immunomodulatory Medications for Patients With Relapsing Polychondritis

Takayasu Arteritis (TAK) (1)

NCT	Acronym	Phase	Status	Title
NCT07013838	—	P4	not yet recruiting	The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis

Healthy Adult Male (1)

NCT	Acronym	Phase	Status	Title
NCT07181694	—	P1	recruiting	A Study of Pharmacokinetics, Safety, and Immunogenicity of BCD-057 100 mg/mL, BCD-057 50 mg/mL, and Humira 100 mg/mL in Healthy Subjects

Effect of Drug (1)

NCT	Acronym	Phase	Status	Title
NCT06742606	—	Early P1	not yet recruiting	Efficacy of Biological Therapy in Pediatric Inflammatory Bowel Disease

Behcet Syndrome, Intestinal Type (1)

NCT	Acronym	Phase	Status	Title
NCT06849908	—	P2	recruiting	Baricitinib in the Treatment of Intestinal Behçet's Syndrome

IBD (1)

NCT	Acronym	Phase	Status	Title
NCT03938701	STRATIFY	P2	recruiting	Fluorescence Imaging of IBD and RA Using Adalimumab-800CW

Diabetes Mellitus, Type 1 (1)

NCT	Acronym	Phase	Status	Title
NCT02586831	DIPIT	P1/P2	withdrawn	Diabetes Islet Preservation Immune Treatment

Inflammatory Arthritis (1)

NCT	Acronym	Phase	Status	Title
NCT06037811	—	P2	recruiting	Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis

Non Infectious Uveitis (1)

NCT	Acronym	Phase	Status	Title
NCT06258915	FOCUS	P3	not yet recruiting	Treatment FOr Corticosteroid Dependent UveitiS

Retinitis Pigmentosa (RP) (1)

NCT	Acronym	Phase	Status	Title
NCT07348588	ADARET	P1/P2	active not recruiting	Intravitreal Adalimumab in Inherited and Degenerative Retinal Diseases

Benign Prostatic Hyperplasia (BPH) (1)

NCT	Acronym	Phase	Status	Title
NCT06062875	—	P2	recruiting	Effects of TNF Blockade on Human BPH/LUTS

Behcet's Uveitis (1)

NCT	Acronym	Phase	Status	Title
NCT05874505	UVB	P2	not yet recruiting	"Comparison of the Efficacy and Safety of Adalimumab to That of Tocilizumab in Severe Uveitis of Behçet's Disease"

Psoriasi (1)

NCT	Acronym	Phase	Status	Title
NCT05889338	—	N/A	unknown	Effect of Adalimumab Therapy on Psoriasis Patient

Tuberculous Meningitis (1)

NCT	Acronym	Phase	Status	Title
NCT05590455	TIMPANI	P2	recruiting	Tnf Inhibitors to Reduce Mortality in HIV-1 Infected PAtients With Tuberculosis meNIngitis

Immunoclassification (1)

NCT	Acronym	Phase	Status	Title
NCT05503875	—	N/A	recruiting	Immunoclassification of Psoriasis: a Strategy for Precision Medicine

Arthritis, Psoriatic (1)

NCT	Acronym	Phase	Status	Title
NCT05640245	—	P2	completed	Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis

Skin Inflammation (1)

NCT	Acronym	Phase	Status	Title
NCT05535738	—	P2/P3	active not recruiting	Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation

Frozen Shoulder (1)

NCT	Acronym	Phase	Status	Title
NCT05299242	Anti-FreazeF	P2/P3	completed	The Anti-Freaze-F Study- "Anti-TNF for Treatment of Frozen Shoulder - a Feasibility Study"

Non-infectious Intermediate Posterior- or Pan-uveitis (1)

NCT	Acronym	Phase	Status	Title
NCT05414201	—	P4	completed	A Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Participants Requiring High Dose Corticosteroids for Active Non-Infectious Intermediate, Posterior, or Pan-Uveitis

Mild to Moderate COVID-19 (1)

NCT	Acronym	Phase	Status	Title
NCT04705844	COMBAAT	P3	withdrawn	Study of Adalimumab or Placebo in Patients With Mild to Moderate COVID-19 (COMBAAT)

Uveitis, Anterior (1)

NCT	Acronym	Phase	Status	Title
NCT05015335	—	P4	unknown	The Efficacy and Safety of Adalimumab in Non-infectious Anterior Pediatric Uveitis With Peripheral Vascular Leakage

Vogt-Koyanagi-Harada Disease (1)

NCT	Acronym	Phase	Status	Title
NCT05590416	—	N/A	recruiting	A Study of Adalimumab in Acute Vogt-Koyanagi-Harada Disease

Cutaneous Melanoma (1)

NCT	Acronym	Phase	Status	Title
NCT04551352	TYRP1	P1	completed	A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas

Infection (1)

NCT	Acronym	Phase	Status	Title
NCT04115423	—	N/A	unknown	A Retrospective Cohort Study on the Risk of Serious Infections in Rheumatoid Arthritis Patients Receiving Tocilizumab

RA (1)

NCT	Acronym	Phase	Status	Title
NCT04224194	—	P3	completed	Auto-injector Real Life Handling in Patients

FSGS (1)

NCT	Acronym	Phase	Status	Title
NCT04009668	—	P2	completed	Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease

Healthy Participants (1)

NCT	Acronym	Phase	Status	Title
NCT04439929	—	P1	completed	Comparative Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of Adalimumab in Healthy Subjects

Phase 1 (1)

NCT	Acronym	Phase	Status	Title
NCT03983876	PFS	P1	completed	PK, Safety and Tolerability Study of AVT02 (Adalimumab) Pre-filled Syringe (PFS) vs, AVT02 Autoinjector (AI)

Arthritis, Rheumatoid (RA) (1)

NCT	Acronym	Phase	Status	Title
NCT04089514	PROPER	N/A	completed	A Real-world Study of Imraldi® Use

Chronic Nonbacterial Osteomyelitis (1)

NCT	Acronym	Phase	Status	Title
NCT04725422	CHOIR	N/A	recruiting	CHronic Nonbacterial Osteomyelitis International Registry

Pain (1)

NCT	Acronym	Phase	Status	Title
NCT03607903	—	P1/P2	completed	Adalimumab Microneedles in Healthy Volunteers

Mucopolysaccharidosis I (1)

NCT	Acronym	Phase	Status	Title
NCT03153319	—	P1/P2	active not recruiting	Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI

Immune System Disorder (1)

NCT	Acronym	Phase	Status	Title
NCT03357939	—	P1	completed	Phase I Study of HLX3 vs Adalimumab in Chinese Healthy Subjects

ULCERATIVE COLITIS (1)

NCT	Acronym	Phase	Status	Title
NCT02878083	DETECT	N/A	terminated	Development of a Biomarker of Efficacy of Vedolizumab (EnTyvio®) in Patients With ulcErative ColiTis (DETECT)

Arthritis,Rheumatoid (1)

NCT	Acronym	Phase	Status	Title
NCT02963402	—	N/A	completed	Immunoregulatory Mechanisms of Treg Cells Induced by Tocilizumab

Bioequivalence (1)

NCT	Acronym	Phase	Status	Title
NCT03273192	—	P1	completed	A Study Of CinnoRA (Adalimumab-CinnaGen) And Adalimumab (Humira) In Healthy Subjects

AS (1)

NCT	Acronym	Phase	Status	Title
NCT02893254	—	P3	completed	Efficacy and Safety of IBI303 in Adult Patients With Active Ankylosing Spondylitis

Healthy Volunteer (1)

NCT	Acronym	Phase	Status	Title
NCT02927353	DMB-3113-1	P1	completed	A Phase 1 Pharmacokinetic Bioequivalence Study of DMB-3113 and Adalimumab in Healthy Japanese Adult Male Subjects

Dupuytren's Disease (1)

NCT	Acronym	Phase	Status	Title
NCT03180957	RIDD	P2	completed	Repurposing Anti-TNF for Treating Dupuytren's Disease

Ankylosing Spondyloarthritis (1)

NCT	Acronym	Phase	Status	Title
NCT02634541	PETSPA	P4	unknown	Adalimumab in Alleviating Inflammation in Patients With Axial Spondyloarthritis

Active Rheumatoid Arthritis (1)

NCT	Acronym	Phase	Status	Title
NCT03172325	—	P3	completed	Study to Demonstrate Non-Inferior Efficacy and Safety of CinnoRA® Versus Humira® for Treatment of Active RA

Generalized Pustular Psoriasis (GPP) (1)

NCT	Acronym	Phase	Status	Title
NCT02533375	GPP	P3	completed	Study to Investigate Efficacy and Safety of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)

Colitis, Ulcerative (1)

NCT	Acronym	Phase	Status	Title
NCT02497469	IV	P3	completed	An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis

Mucopolysaccharidosis Type I (1)

NCT	Acronym	Phase	Status	Title
NCT02437253	—	P1/P2	completed	Effects of Adalimumab in Mucopolysaccharidosis Types I, II and VI

Osteoarthritis, Knee (1)

NCT	Acronym	Phase	Status	Title
NCT02471118	OKINADA	P2	completed	Osteoarthritis of the Knee, Inflammation, and the Effect of Adalimumab (OKINADA)

CD (1)

NCT	Acronym	Phase	Status	Title
NCT03306446	CURE	P4	unknown	Changing the coUrse of cRohn's Disease With an Early Use of Adalimumab

Anaplastic Thyroid Cancers (1)

NCT	Acronym	Phase	Status	Title
NCT02516774	TAM-RT	P1	withdrawn	A Trial of Adalimumab Combined to Chemotherapy and Radiotherapy in Patients With Anaplastic Thyroid Cancers

Inflammation (1)

NCT	Acronym	Phase	Status	Title
NCT02097264	—	P2	withdrawn	A Trial Investigating the Mechanism of Action of NNC0109-0012 (Anti-IL-20 mAb) Through Synovial Biopsies in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate

Healthy Subjects (1)

NCT	Acronym	Phase	Status	Title
NCT02237729	B538-07	P1	completed	A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira) In Healthy Subjects (REFLECTIONS B538-07))

Rhematoid Arthritis (1)

NCT	Acronym	Phase	Status	Title
NCT02187055	ORAL STRATEGY	P4	completed	An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate

Moderate to Severe Crohn's Disease (1)

NCT	Acronym	Phase	Status	Title
NCT02148718	RAPIDA	P4	completed	Rapidity of Response to Adalimumab Treatment in Patients With Crohn´s Disease

Nail Psoriasis (1)

NCT	Acronym	Phase	Status	Title
NCT02016482	—	P3	completed	A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis

Netherton Syndrome (1)

NCT	Acronym	Phase	Status	Title
NCT02113904	AntiTNF-SN	P2	completed	Clinical Trial Using Humira in Netherton Syndrome

Plaque Type Psoriasis (1)

NCT	Acronym	Phase	Status	Title
NCT02016105	ADACCESS	P3	completed	Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and Humira

Arthritis; Behcet (1)

NCT	Acronym	Phase	Status	Title
NCT01497717	—	P3	completed	Efficacy of Humira in Behcet Patients With Arthritis

Psoriasis, Arthritic (1)

NCT	Acronym	Phase	Status	Title
NCT01695239	SPIRIT-P1	P3	completed	A Study of Ixekizumab in Participants With Active Psoriatic Arthritis

Crohn´s Disease (1)

NCT	Acronym	Phase	Status	Title
NCT01564823	APPRECIA	P3	completed	Adalimumab on Preventing Post-chirurgic Recurrence on Crohn´s Disease

Moderate to Severe Plaque Psoriasis (1)

NCT	Acronym	Phase	Status	Title
NCT01644396	—	P4	completed	An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation

Oligoarthritis (1)

NCT	Acronym	Phase	Status	Title
NCT04154852	ADEOS	P2	completed	ADalimumab in Persistent Early Oligoarthrits Study (ADEOS)

Interstitial Cystitis (1)

NCT	Acronym	Phase	Status	Title
NCT01295814	—	P3	completed	Efficacy Study of Adalimumab to Treat Interstitial Cystitis

Moderate to Severe Psoriasis. (1)

NCT	Acronym	Phase	Status	Title
NCT01237262	ELIDACE	P4	unknown	Evaluation of Lymphocytic Infiltrate, Dendritic Cells and Cytokines Expression in Psoriatic Lesion and Normal Skin Before and After TNF Alfa Inhibitors Therapy

Intestinal Behçet's Disease (1)

NCT	Acronym	Phase	Status	Title
NCT01243671	—	P3	completed	A Study of Adalimumab in Japanese Subjects With Intestinal Behçet's Disease

Enthesitis Related Arthritis (ERA) (1)

NCT	Acronym	Phase	Status	Title
NCT01166282	—	P3	completed	A Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Enthesitis Related Arthritis

Age-Related Macular Degeneration (1)

NCT	Acronym	Phase	Status	Title
NCT01136252	—	P2	completed	Intravitreal Adalimumab in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration

Peripheral Spondyloarthritis (1)

NCT	Acronym	Phase	Status	Title
NCT01064856	—	P3	completed	Study of Adalimumab in Participants With Peripheral Spondyloarthritis (SpA)

Focal Segmental Glomerulosclerosis (1)

NCT	Acronym	Phase	Status	Title
NCT00814255	FONTII	P2	completed	Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial

Innate Immunity (1)

NCT	Acronym	Phase	Status	Title
NCT02252809	—	Early P1	completed	Effect of Anti-Inflammatory Agents on Biological Responses to Endotoxin Inhalation in Healthy Subjects

Crohn's Disease With Perianal Fistulas (1)

NCT	Acronym	Phase	Status	Title
NCT00736983	Adafi	P3	completed	Adalimumab in Combination With Ciprofloxacin/Placebo Treatment of Perianal Fistulas in Crohn's

Juvenile Rheumatoid Arthritis (1)

NCT	Acronym	Phase	Status	Title
NCT00690573	—	P3	completed	Safety, Efficacy, and Pharmacokinetics of Adalimumab in Japanese Children With Juvenile Rheumatoid Arthritis

SPONDYLOARTHRITIS (1)

NCT	Acronym	Phase	Status	Title
NCT00726804	SPARTA	P4	terminated	Discontinuation of TNF-alpha Inhibitors in Patients With Spondyloarthritis

Asthma (1)

NCT	Acronym	Phase	Status	Title
NCT00512863	—	P2	withdrawn	A Dose-Finding Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Adalimumab in Subjects With Refractory Asthma

Hermanski-Pudlak Syndrome (1)

NCT	Acronym	Phase	Status	Title
NCT00514982	—	P2	withdrawn	Medical Treatment of Colitis in Patients With Hermansky-Pudlak Syndrome

Disc Prolapse (1)

NCT	Acronym	Phase	Status	Title
NCT01510548	ADALISKIAS	P3	unknown	ADALISKIAS: Adalimumab for Acute Disc Prolapse

Erosive Osteo-Arthritis (1)

NCT	Acronym	Phase	Status	Title
NCT00296894	—	P2	completed	Study to Evaluate the Efficacy of Adalimumab in Patients With Erosive Osteoarthritis of the Interphalangeal Finger Joints

Giant Cell Arteritis (1)

NCT	Acronym	Phase	Status	Title
NCT00305539	HECTHOR	P3	completed	HECTHOR: Humira to Spare Steroids in Giant Cell Arteritis

Focal Glomerulosclerosis (1)

NCT	Acronym	Phase	Status	Title
NCT00193648	FSGS	P1	completed	Pilot Studies of Novel Therapies to Treat Resistant Focal Segmental Glomerulosclerosis (FSGS)

Sciatica (1)

NCT	Acronym	Phase	Status	Title
NCT00470509	ASAS	P2	completed	Adalimumab in Severe and Acute Sciatica

Spondylarthropathies (1)

NCT	Acronym	Phase	Status	Title
NCT00133315	—	P4	completed	TNFalfa Blocking Treatment of Spondylarthropathies

Arthritis, Juvenile Idiopathic (1)

NCT	Acronym	Phase	Status	Title
NCT00048542	JIA	P3	completed	Study of Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis (JIA)

Adalimumab pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

Acronym	NCT	Phase	Status	Indication	Enrollment	PubMed
CD	NCT07510191	P4	recruiting	Crohn Disease (CD)	312	—
SMOOTH	NCT06390436	P4	not yet recruiting	Uveitis	320	—
PATHFINDER	NCT05928039	P4	recruiting	Crohn Disease	297	—
VEDIAN	NCT06180382	P4	recruiting	Crohn's Disease	220	—
CONTROL	NCT04183608	P4	recruiting	Ulcerative Colitis	238	PMID 40243391
IL-17	NCT06833112	P4	not yet recruiting	Ankylosing Spondylitis	10	—
RA-DRUM	NCT06440629	P4	recruiting	Rheumatoid Arthritis	350	—
IV	NCT06045754	P4	recruiting	Crohn's Disease	100	—
CoCroS	NCT03917303	P4	recruiting	Crohn Disease	158	PMID 33947729
FREE	NCT04646187	P4	enrolling by invitation	Inflammatory Bowel Diseases	148	PMID 34732500
ADATOFTAK	NCT05151848	P4	unknown	Takayasu Arteritis	100	—
JAKAR	NCT05502731	P4	unknown	Rheumatoid Arthritis	40	PMID 27993829
FILRA	NCT06527534	P4	recruiting	Rheumatoid Arthritis	30	—
ADJUST	NCT03816397	P4	completed	Uveitis	87	PMID 39863370
CURE	NCT03306446	P4	unknown	CD	203	—
ADDORA	NCT04194827	P4	unknown	Rheumatoid Arthritis	267	PMID 24326008
BioIBD	NCT03885713	P4	completed	Inflammatory Bowel Diseases	180	PMID 26353983
RECAST	NCT05164198	P4	unknown	Ankylosing Spondylitis	448	—
SPEED	NCT03739853	P4	completed	Psoriatic Arthritis	192	PMID 38826570
STARA	NCT01793519	P4	unknown	Rheumatoid Arthritis	290	PMID 41045868
ADDORA-low	NCT04222920	P4	completed	Rheumatoid Arthritis	78	PMID 28939629
BIORA-PAIN	NCT04255134	P4	completed	Rheumatoid Arthritis	18	PMID 38755699
HS-COST	NCT03221621	P4	unknown	Hidradenitis Suppurativa	128	—
CD	NCT02764762	P4	completed	Crohn Disease	55	PMID 37743037
RAFTING	NCT03100253	P4	terminated	Rheumatoid Arthritis	208	—
STRIDENT	NCT03220841	P4	unknown	Crohn Disease	78	PMID 34890567
AMiRA	NCT03619876	P4	terminated	Rheumatoid Arthritis	11	PMID 12508387
RCT	NCT02852694	P4	completed	Crohn's Disease	192	PMID 33492239
TARGET	NCT02374021	P4	completed	Arthritis, Rheumatoid	159	PMID 36450449
RA-BioStop	NCT01602302	P4	terminated	Rheumatoid Arthritis	40	—
TNF	NCT02092467	P4	completed	Arthritis, Rheumatoid	4,372	PMID 35081280
RA	NCT03737708	P4	completed	Rheumatoid Arthritis (RA)	21	—
CONTROL	NCT02814175	P4	completed	Psoriatic Arthritis	246	PMID 38288922
BROCAII	NCT02035800	P4	unknown	RheumatoId Arthritis	120	—
SHARPS	NCT02808975	P4	completed	Hidradenitis Suppurativa (HS)	206	PMID 34406349
SPIRIT-H2H	NCT03151551	P4	completed	Psoriatic Arthritis	566	PMID 33200394
BEAT-IBD	NCT03059849	P4	withdrawn	Crohn Disease	0	—
TURA	NCT02056184	P4	completed	Rheumatoid Arthritis	183	—
PAILOT	NCT02256462	P4	completed	Crohn's Disease	82	PMID 31793630
PREDICTRA	NCT02198651	P4	completed	Rheumatoid Arthritis	149	PMID 29490959
TNF	NCT02492217	P4	completed	Ankylosing Spondylitis	69	—
PETSPA	NCT02634541	P4	unknown	Ankylosing Spondyloarthritis	60	—
STRIKE	NCT02897115	P4	terminated	Axial Spondyloarthritis	22	—
Muscara	NCT01609205	P4	completed	Rheumatoid Arthritis	60	—
MOA	NCT00932113	P4	completed	Psoriasis	33	PMID 18047523
CURE	NCT00480272	P4	completed	Rheumatoid Arthritis	251	—
RAPIDA	NCT02148718	P4	completed	Moderate to Severe Crohn's Disease	100	—
ORAL STRATEGY	NCT02187055	P4	completed	Rhematoid Arthritis	1,152	PMID 38958913
VIP-E	NCT01866592	P4	completed	Psoriasis	81	—
VIP	NCT01553058	P4	completed	Psoriasis	97	PMID 31163241
RA	NCT01500278	P4	completed	Rheumatoid Arthritis	915	PMID 27863807
EUS	NCT00517296	P4	completed	Crohn Disease	21	—
SWITCH	NCT01295151	P4	completed	Rheumatoid Arthritis	122	PMID 32859608
RADAR	NCT01162421	P4	completed	Rheumatoid Arthritis	77	—
ORBIT	NCT01021735	P4	completed	Rheumatoid Arthritis	302	PMID 27197690
COMARIS	NCT01895764	P4	completed	Ankylosing Spondylitis	110	PMID 31958280
CASTIP	NCT01088165	P4	unknown	Psoriasis	66	—
INTASAH	NCT01174186	P4	completed	Spondyloarthritis	30	—
ASIM	NCT01029847	P4	completed	Spondyloarthritis	49	PMID 29556419
ROC	NCT01000441	P4	completed	Rheumatoid Arthritis	300	PMID 27654603
AFORA	NCT01382160	P4	completed	Rheumatoid Arthritis	69	PMID 38049981
REWARD	NCT01405326	P4	unknown	Rheumatoid Arthritis	160	—
MUSICA	NCT01185288	P4	completed	Rheumatoid Arthritis	309	PMID 27214046
DANISH	NCT00477893	P4	unknown	Spondyloarthritis	52	PMID 26414004
ADMIRE	NCT00808509	P4	completed	Arthritis, Rheumatoid	33	PMID 26819752
MTX	NCT01283971	P4	terminated	Rheumatoid Arthritis	96	—
SPARTA	NCT00726804	P4	terminated	SPONDYLOARTHRITIS	7	—
HUPSA	NCT01465438	P4	completed	Psoriatic Arthritis	42	PMID 24369412
ELIDACE	NCT01237262	P4	unknown	Moderate to Severe Psoriasis.	20	PMID 19641206
RA	NCT00796705	P4	terminated	Rheumatoid Arthritis	13	PMID 20386564
OPTIMA	NCT00420927	P4	completed	Rheumatoid Arthritis	1,032	PMID 30076156
VIVIR	NCT00761514	P4	terminated	Rheumatoid Arthritis	14	—
HURRAH	NCT00696059	P4	completed	Rheumatoid Arthritis	52	PMID 27682742
HERO	NCT00234897	P4	completed	Rheumatoid Arthritis	1,938	—
LY3009104	NCT04088409	P3	active not recruiting	Uveitis	30	PMID 34627340
LY2439821	NCT04527380	P3	active not recruiting	Juvenile Psoriatic Arthritis	101	PMID 41785908
PLANETA-KIDS	NCT06640517	P3	active not recruiting	Plaque Psoriasis	140	—
LEVENTA	NCT06333210	P3	active not recruiting	Axial Spondyloarthritis	421	—
FOCUS	NCT06258915	P3	not yet recruiting	Non Infectious Uveitis	120	—
SELECT-COMPARE	NCT02629159	P3	active not recruiting	Rheumatoid Arthritis	1,629	PMID 34041702
SELECT- SWITCH	NCT05814627	P3	active not recruiting	Rheumatoid Arthritis	487	PMID 41991443
Co-THEIA	NCT04798755	P3	unknown	Uveitis	192	PMID 35318229
ADVISE	NCT03828019	P3	completed	Uveitis	227	PMID 37172782
SELECT - PsA 1	NCT03104400	P3	completed	Psoriatic Arthritis	1,705	PMID 34636026
COMBAAT	NCT04705844	P3	withdrawn	Mild to Moderate COVID-19	0	—
AScalate	NCT03906136	P3	completed	Axial Spondyloarthritis	304	PMID 32998926
BE OPTIMAL	NCT03895203	P3	completed	Psoriatic Arthritis	852	PMID 41381988
SURPASS	NCT03259074	P3	completed	Ankylosing Spondylitis	859	PMID 33978600
IntnsificADA	NCT04404517	P3	unknown	Inflammatory Bowel Diseases	20	—
SEAVUE	NCT03464136	P3	completed	Crohn Disease	386	PMID 41258994
PENGUIN 1	NCT04115748	P3	terminated	Psoriatic Arthritis	67	—
SARIL-RA-MONARCH	NCT02332590	P3	completed	Rheumatoid Arthritis	369	PMID 33081825
AJIBIOREM	NCT02840175	P3	completed	Juvenile Idiopathic Arthritis	62	—
VOYAGE 2	NCT02207244	P3	completed	Psoriasis	992	PMID 37715294
VOYAGE 1	NCT02207231	P3	completed	Psoriasis	837	PMID 39153060
HIBISCUS II	NCT02171429	P3	completed	Ulcerative Colitis	358	—
HIBISCUS I	NCT02163759	P3	completed	Ulcerative Colitis	358	PMID 32445184
BE SURE	NCT03412747	P3	completed	Chronic Plaque Psoriasis	478	PMID 36689515
EXCEED 1	NCT02745080	P3	completed	Psoriatic Arthritis	853	PMID 32386593
CREDO 2	NCT02760407	P3	completed	Rheumatoid Arthritis	1,648	PMID 36001712
FINCH 1	NCT02889796	P3	completed	Rheumatoid Arthritis	1,759	PMID 38985247
IV	NCT02497469	P3	completed	Colitis, Ulcerative	771	PMID 31553834
COAST-V	NCT02696785	P3	completed	Spondyloarthritis	341	PMID 35429281
VISUAL III	NCT01148225	P3	completed	Uveitis	424	PMID 33157077
SPIRIT A1	NCT01870284	P3	withdrawn	Spondylitis, Ankylosing	0	—
REFLECTIONS B538-02	NCT02480153	P3	completed	Rheumatoid Arthritis	597	PMID 36180101
SPIRIT-P1	NCT01695239	P3	completed	Psoriasis, Arthritic	417	PMID 29247148
ADMYRA	NCT02744755	P3	completed	Rheumatoid Arthritis	353	PMID 33119861
MTX	NCT02150473	P3	terminated	Rheumatoid Arthritis	21	—
GPP	NCT02533375	P3	completed	Generalized Pustular Psoriasis (GPP)	10	—
PsOsim	NCT02489227	P3	completed	Plaque Psoriasis	545	—
CLEAR	NCT02196701	P3	completed	Psoriasis	46	—
CALM	NCT01235689	P3	completed	Crohn's Disease	252	PMID 32224129
PIONEER (OLE)	NCT01635764	P3	completed	Hidradenitis Suppurativa	508	—
SIRROUND-H	NCT02019472	P3	completed	Arthritis, Rheumatoid	559	PMID 29483080
POPART	NCT01629628	P3	unknown	Crohn Disease	100	PMID 38137669
CADHUM	NCT01674413	P3	withdrawn	Crohn's Disease	0	—
ADACCESS	NCT02016105	P3	completed	Plaque Type Psoriasis	465	PMID 39545451
ADAP	NCT01670240	P3	completed	Ulcerative Colitis	13	—
OPAL BROADEN	NCT01877668	P3	completed	Psoriatic Arthritis	422	PMID 36526796
RA-BEAM	NCT01710358	P3	completed	Rheumatoid Arthritis	1,307	PMID 29680881
Visual II	NCT01124838	P3	completed	Uveitis	261	—
InspirAda	NCT01550965	P3	completed	Ulcerative Colitis	463	PMID 28981846
RA-COMPARE	NCT01764997	P3	terminated	Rheumatoid Arthritis	776	—
APPRECIA	NCT01564823	P3	completed	Crohn´s Disease	86	PMID 28402454
VISUAL l	NCT01138657	P3	completed	Uveitis	239	PMID 27602665
ADALISKIAS	NCT01510548	P3	unknown	Disc Prolapse	90	PMID 15115710
PIONEER II	NCT01468233	P3	completed	Hidradenitis Suppurativa (HS)	326	PMID 27518661
ADACAL	NCT01562951	P3	terminated	Crohn's Disease	15	—
PIONEER I	NCT01468207	P3	completed	Hidradenitis Suppurativa (HS)	307	PMID 39141589
JIA	NCT00775437	P3	completed	Juvenile Idiopathic Arthritis	32	PMID 24487484
CONCERTO	NCT01185301	P3	completed	Early Rheumatoid Arthritis	395	PMID 29402521
PREMIER	NCT00195663	P3	completed	Early Rheumatoid Arthritis	799	PMID 22045836
Adafi	NCT00736983	P3	completed	Crohn's Disease With Perianal Fistulas	76	PMID 23525574
OPERA	NCT00660647	P3	completed	Arthritis, Rheumatoid	180	PMID 29142030
HECTHOR	NCT00305539	P3	completed	Giant Cell Arteritis	69	PMID 23897775
JIA	NCT00048542	P3	completed	Arthritis, Juvenile Idiopathic	171	PMID 18716298
ATLAS	NCT00085644	P3	completed	Ankylosing Spondylitis	315	PMID 19686597
CLASSICII	NCT00055497	P3	completed	Crohn's Disease	276	PMID 22344964
CLASSICII	NCT01070303	P3	completed	Crohn's Disease	177	—
ACCESS	NCT00427921	P3	completed	Crohn's Disease	304	—
BELIEVE	NCT00574249	P3	completed	Chronic Plaque Psoriasis	730	PMID 23178916
PRIDE	NCT00513370	P3	completed	Psoriasis	203	—
CHOICE	NCT00338650	P3	completed	Crohn's Disease	1,000	PMID 20955442
ACCLAIM	NCT00427362	P3	completed	Psoriatic Arthritis	127	PMID 20595284
RHAPSODY	NCT00478660	P3	completed	Ankylosing Spondylitis	1,250	PMID 18662932
CHAMPION	NCT00235820	P3	completed	Psoriasis	271	—
STEREO	NCT00235885	P3	completed	Psoriatic Arthritis	445	PMID 25834212
CHARM	NCT00077779	P3	completed	Crohn's Disease	854	PMID 34546360
ReAct	NCT00448383	P3	completed	Rheumatoid Arthritis	6,610	PMID 18163417
BOOSTERS	NCT07268534	P2	not yet recruiting	Folliculitis Decalvans (FD)	120	—
PRISMS	NCT06996652	P2	not yet recruiting	REM Sleep Behavior Disorder	108	—
PROSECT RP	NCT06941376	P2	recruiting	Relapsing Polychondritis	20	—
TIMPANI	NCT05590455	P2	recruiting	Tuberculous Meningitis	130	—
IV	NCT06257875	P2	active not recruiting	Ulcerative Colitis	156	—
UVB	NCT05874505	P2	not yet recruiting	Behcet's Uveitis	60	—
STRATIFY	NCT03938701	P2	recruiting	IBD	36	—
IVAS	NCT02706704	P2	recruiting	Uveitis	32	PMID 21099452
AS	NCT06242652	P2	unknown	Ankylosing Spondylitis	250	—
DUET	NCT04655807	P2	withdrawn	Crohn Disease	0	PMID 40357993
LYRA	NCT04988308	P2	terminated	Hidradenitis Suppurativa	151	—
MARKET	NCT05372939	P2	completed	Ulcerative Colitis	51	—
RUBI	NCT02929251	P2	completed	Uveitis	112	PMID 41643758
OKINADA	NCT02471118	P2	completed	Osteoarthritis, Knee	62	—
RIDD	NCT03180957	P2	completed	Dupuytren's Disease	140	PMID 35949922
RA	NCT03823391	P2	completed	Rheumatoid Arthritis (RA)	48	PMID 36512671
RA	NCT02833350	P2	completed	Rheumatoid Arthritis	578	—
AntiTNF-SN	NCT02113904	P2	completed	Netherton Syndrome	11	—
ADEOS	NCT04154852	P2	completed	Oligoarthritis	22	—
TELLUS	NCT02393378	P2	terminated	Rheumatoid Arthritis	7	—
UC	NCT01716039	P2	terminated	Ulcerative Colitis	22	PMID 22326435
MTX	NCT02349451	P2	completed	Psoriatic Arthritis	240	PMID 29855175
FONTII	NCT00814255	P2	completed	Focal Segmental Glomerulosclerosis	32	PMID 26198842
OSKIRA -4	NCT01264770	P2	terminated	Rheumatoid Arthritis	644	PMID 25074688
X-PLORE	NCT01483599	P2	completed	Psoriasis	293	PMID 26154787
OSKIRA 4 SS	NCT02092961	P2	terminated	Rheumatoid Arthritis	198	—
RA	NCT01712178	P2	completed	Rheumatoid Arthritis	100	—
DMARD	NCT01225393	P2	completed	Rheumatoid Arthritis	211	PMID 25359150
AUGUST II	NCT00595413	P2	completed	Rheumatoid Arthritis	311	PMID 21452294
HIDRI2007	NCT00827996	P2	completed	Hidradenitis Suppurativa	10	—
ASAS	NCT00470509	P2	completed	Sciatica	61	PMID 20506391

Terminated and withdrawn Adalimumab trials (41)

Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.

NCT04643483withdrawnA Study to Test Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Crohn's Disease
NCT02586831withdrawnDiabetes Islet Preservation Immune Treatment
NCT04655807withdrawnA Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease
NCT04988308terminatedA Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa
NCT04705844withdrawnStudy of Adalimumab or Placebo in Patients With Mild to Moderate COVID-19 (COMBAAT)
NCT04132388withdrawnHidradenitis Suppurativa Patient Experience With Humira Treatment
NCT03100253terminatedRheumatoid Arthritis Treatment After First Anti-TNF INvestiGation
NCT03619876terminatedEffects of Abatacept on Myocarditis in Rheumatoid Arthritis
NCT04115748terminatedStudy to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy
NCT02878083terminatedDevelopment of a Biomarker of Efficacy of Vedolizumab (EnTyvio®) in Patients With ulcErative ColiTis (DETECT)
NCT01602302terminatedUltrasound and Withdrawal of Biological DMARDs in Rheumatoid Arthritis
NCT03016260terminatedRABIOPRED - a Validation Study of Theranostic Test to PREDict Treatment Response of Anti-TNFα BIologicals in Rheumatoid Arthritis
NCT03059849withdrawnBrief Escalation of Adalimumab Treatment for Prevention of Clinical Relapse in IBD
NCT01986127terminatedAdalimumab Intralesional in Intestinal Strictures of Crohn's Disease Patients
NCT01870284withdrawnStudy of Ixekizumab in Participants With Active Ankylosing Spondylitis (AS)
NCT02897115terminatedA Study Treating Participants With Early Axial Spondyloarthritis (axSpA) Taking an Intense Treatment Approach Versus Routine Treatment
NCT02150473terminatedThe Effect of Adalimumab Plus Methotrexate (MTX) Versus Placebo Plus MTX on Cartilage in (RA) Patients
NCT02393378terminatedNamilumab vs Adalimumab in Participants With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to Methotrexate
NCT01716039terminatedPharmacokinetics of Adalimumab With Methotrexate for Treatment of Patients With Ulcerative Colitis (UC)
NCT01674413withdrawnCalprotectin-Directed Humira® Maintenance Therapy (CADHUM)
NCT02516774withdrawnA Trial of Adalimumab Combined to Chemotherapy and Radiotherapy in Patients With Anaplastic Thyroid Cancers
NCT02097264withdrawnA Trial Investigating the Mechanism of Action of NNC0109-0012 (Anti-IL-20 mAb) Through Synovial Biopsies in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
NCT01764997terminatedAn Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate
NCT01562951terminatedAssessment of Mucosal Activity to Improve the Prognosis of Patients With Crohn's Disease Treated With Immunosuppressants
NCT01264770terminatedEvaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
NCT02092961terminatedRandomised Double-Blind, Placebo-Controlled, Parallel Group Study in Patients With Active Rheumatoid Arthritis:Magnetic Resonance Imaging Sub-Study
NCT01283971terminatedA Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor
NCT00726804terminatedDiscontinuation of TNF-alpha Inhibitors in Patients With Spondyloarthritis
NCT00298272terminatedSafety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis
NCT00514982withdrawnMedical Treatment of Colitis in Patients With Hermansky-Pudlak Syndrome
NCT00796705terminatedSwitching Anti-TNF-Alpha Agents in Rheumatoid Arthritis (RA)
NCT01078610withdrawnSafety and Effectiveness and Effect on Quality of Life and Work Productivity of Humira in Patients With Psoriatic Arthritis in Clinical Routine
NCT00972218withdrawnEffectiveness and Safety of Spondylitis Related to Inflammatory Bowel Disease
NCT01012570terminatedThe Effect of Adalimumab on the Bone Microstructure in Crohn's Disease (CD) Patients
NCT00724672withdrawnA Study of Immune Cells in Patients With Rheumatoid Arthritis During Different Types of Anti-TNF Alpha Treatments (Study P05521)
NCT00311246terminatedTrial of Adalimumab in Progressive Sarcoidosis
NCT00761514terminatedEvaluation of Quality of Life Changes in Puerto Rican Subjects With Active Rheumatoid Arthritis Treated With Humira
NCT00690911withdrawnStudy to Determine the Efficacy of Adalimumab in the Treatment of Cutaneous Sarcoidosis
NCT00512863withdrawnA Dose-Finding Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Adalimumab in Subjects With Refractory Asthma
NCT00690846withdrawnStudy to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum
NCT00233558terminatedOpen-Label Steroid Reduction Study of Adalimumab With Methotrexate in Patients With Active Rheumatoid Arthritis

All Adalimumab trials (463)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT ID	Acronym	Title	Phase	Status	Enrollment	Sponsor	Started
NCT04725422	CHOIR	CHronic Nonbacterial Osteomyelitis International Registry	—	recruiting	2,000	Seattle Children's Hospital	Aug 2018
NCT01706692	SDNTT	Swiss Dermatology Network of Targeted Therapies (SDNTT)	—	recruiting	1,121	Swiss Dermatology Network for Targeted Therapies	Feb 2011
NCT07061574	WAVE T1D	A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes	P1/P2	recruiting	120	City of Hope Medical Center	Mar 2026
NCT07352566		Utilization of a Microdevice for Psoriasis and Atopic Dermatitis	P4	not yet recruiting	10	University of California, San Francisco	Aug 2026
NCT07268534	BOOSTERS	Biologics in Folliculitis Decalvans : an Adaptative Trial Research	P2	not yet recruiting	120	Assistance Publique - Hôpitaux de Paris	Apr 2026
NCT07510191	CD	TNFi Plus Low-Dose Upadacitinib vs TNFi Intensification in Crohn's Disease With Suboptimal Response	P4	recruiting	312	Sixth Affiliated Hospital, Sun Yat-sen University	Mar 2026
NCT06996652	PRISMS	An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)	P2	not yet recruiting	108	Yale University	Jun 2026
NCT06390436	SMOOTH	Therapeutic Drug Monitoring-baSed adalimuMab De-escalatiOn in nOn-infecTious cHronic Uveitis	P4	not yet recruiting	320	Centre Hospitalier Universitaire de Saint Etienne	Jun 2025
NCT07564505		Post - Marketing Case Registration Study on the Safety and Efficacy of Adalimumab Solution for Injection in Chinese Pediatric Patients With Moderate - to - Severe Active Crohn's Disease	P4	not yet recruiting	30	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	May 2026
NCT03414502		Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response	P3	recruiting	400	University of Nebraska	Dec 2007
NCT07423533		Phase IIb Clinical Study to Assess the Efficacy and Safety of GenSci120 Injection in Patients With Moderately to Severely Active RA Who Have an Inadequate Response to at Least One DMARD	P2	recruiting	450	Changchun GeneScience Pharmaceutical Co., Ltd.	Apr 2026
NCT06037811		Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis	P2	recruiting	30	Tom Appleton	Apr 2024
NCT05928039	PATHFINDER	PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease	P4	recruiting	297	University of Calgary	Oct 2023
NCT06016517		Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis	—	not yet recruiting	18	Tufts Medical Center	May 2026
NCT06180382	VEDIAN	Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration.	P4	recruiting	220	Centre Hospitalier Universitaire de Saint Etienne	Oct 2024
NCT06100744		A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab	P3	recruiting	40	AbbVie	Jul 2024
NCT04088409	LY3009104	A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis	P3	active not recruiting	30	Eli Lilly and Company	Oct 2019
NCT06849908		Baricitinib in the Treatment of Intestinal Behçet's Syndrome	P2	recruiting	56	Peking Union Medical College Hospital	Nov 2024
NCT06926478		Subconjunctival Humira for Boston Keratoprosthesis	P1	not yet recruiting	8	Massachusetts Eye and Ear Infirmary	Jun 2026
NCT06062875		Effects of TNF Blockade on Human BPH/LUTS	P2	recruiting	70	Endeavor Health	Jan 2024
NCT07529925		A Clinical Trail of Adalimumab in Treating Chinese Children With Severe Plaque Psoriasis	P4	not yet recruiting	30	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	May 2026
NCT04183608	CONTROL	A Trial COmparing staNdard of Care Versus Treat to Target With telemonitoRing and Patient Education in Patients With Ulcerative cOlitis Initiating Adalimumab	P4	recruiting	238	Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives	Jan 2020
NCT04527380	LY2439821	A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis	P3	active not recruiting	101	Eli Lilly and Company	Apr 2021
NCT07258641	VOYAGER	Fluorescence Imaging of Adalimumab-680LT and Risankizumab-800CW in Inflammatory Bowel Disease	P1/P2	not yet recruiting	30	University Medical Center Groningen	Jan 2026
NCT07013838		The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis	P4	not yet recruiting	50	Chinese SLE Treatment And Research Group	Jun 2025
NCT06833112	IL-17	Interleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor for the Treatment of Ankylosing Spondylitis	P4	not yet recruiting	10	The Affiliated Hospital Of Guizhou Medical University	Feb 2025
NCT06640517	PLANETA-KIDS	Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Netakimab in Children With Moderate to Severe Plaque Psoriasis	P3	active not recruiting	140	Biocad	Aug 2024
NCT06333210	LEVENTA	Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of BCD-180 in Patients With Axial Spondyloarthritis (LEVENTA)	P3	active not recruiting	421	Biocad	Dec 2023
NCT06941376	PROSECT RP	An Open-Label Study of Effectiveness of Immunomodulatory Medications for Patients With Relapsing Polychondritis	P2	recruiting	20	University of Pennsylvania	Aug 2025
NCT06440629	RA-DRUM	Effect of Proactive Therapeutic Drug Monitoring on Maintenance of Sustained Disease Control in Adults With Rheumatoid Arthritis on a Subcutaneous TNF Inhibitor: The Rheumatoid Arthritis Therapeutic DRUg Monitoring Trial (RA-DRUM)	P4	recruiting	350	Diakonhjemmet Hospital	Aug 2024
NCT05590455	TIMPANI	Tnf Inhibitors to Reduce Mortality in HIV-1 Infected PAtients With Tuberculosis meNIngitis	P2	recruiting	130	ANRS, Emerging Infectious Diseases	Apr 2023
NCT05503875		Immunoclassification of Psoriasis: a Strategy for Precision Medicine	N/A	recruiting	100	Second Affiliated Hospital, School of Medicine, Zhejiang University	Jan 2023
NCT05535738		Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation	P2/P3	active not recruiting	45	Wei-Che Ko	Nov 2022
NCT07491913		Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission	N/A	recruiting	40	Marmara University	Jun 2025
NCT07151937		A Study of LAD191 in Adults With Hidradenitis Suppurativa	P2	recruiting	200	Almirall, S.A.	Nov 2025
NCT06258915	FOCUS	Treatment FOr Corticosteroid Dependent UveitiS	P3	not yet recruiting	120	Assistance Publique - Hôpitaux de Paris	Mar 2024
NCT07138898		Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty	P2	not yet recruiting	80	NYU Langone Health	Sep 2025
NCT06257875	IV	A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis	P2	active not recruiting	156	AbbVie	Mar 2024
NCT02629159	SELECT-COMPARE	A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate	P3	active not recruiting	1,629	AbbVie	Dec 2015
NCT04909801		A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate	P3	active not recruiting	338	Bristol-Myers Squibb	Sep 2021
NCT05874505	UVB	"Comparison of the Efficacy and Safety of Adalimumab to That of Tocilizumab in Severe Uveitis of Behçet's Disease"	P2	not yet recruiting	60	Assistance Publique - Hôpitaux de Paris	Jul 2023
NCT07495644		Efficacy of Different Biological Treatments in Patients With Inflammatory Bowel Disease After One Year of Treatment in Upper Egypt	—	not yet recruiting	95	Assiut University	Mar 2026
NCT06498089		A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis	P4	recruiting	124	Shanghai Zhongshan Hospital	Jun 2024
NCT06045754	IV	A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease	P4	recruiting	100	Takeda	Apr 2024
NCT03153319		Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI	P1/P2	active not recruiting	14	Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center	Jun 2017
NCT05626348		The Clinical Efficacy of Immunomodulators in RA Patients	P4	recruiting	400	Qilu Hospital of Shandong University	Dec 2021
NCT05105347		Efficacy and Safety of Adalimumab Plus Medium Dose Oral Glucocorticosteroid for Refractory Behçet's Uveitis	P4	not yet recruiting	130	Peking Union Medical College Hospital	Nov 2021
NCT07398651		Apremilast and Adalimumab in Psoriatic Arthritis Patients	N/A	not yet recruiting	60	Tanta University	Dec 2026
NCT06742606		Efficacy of Biological Therapy in Pediatric Inflammatory Bowel Disease	Early P1	not yet recruiting	40	Ain Shams University	Jan 2025
NCT07348588	ADARET	Intravitreal Adalimumab in Inherited and Degenerative Retinal Diseases	P1/P2	active not recruiting	30	Centro de Pesquisa Rubens Siqueira	Mar 2024
NCT03917303	CoCroS	Control Crohn Safe Trial	P4	recruiting	158	Maastricht University Medical Center	Dec 2019
NCT03938701	STRATIFY	Fluorescence Imaging of IBD and RA Using Adalimumab-800CW	P2	recruiting	36	University Medical Center Groningen	Aug 2024
NCT05814627	SELECT- SWITCH	Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis	P3	active not recruiting	487	AbbVie	Jun 2023
NCT06310837		Effect of Immunosuppressants With Adalimumab Biosimilars vs Corticosteroids on Noninfectious Uveitis	N/A	active not recruiting	128	Zhongshan Ophthalmic Center, Sun Yat-sen University	Mar 2024
NCT04643483		A Study to Test Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Crohn's Disease	P3	withdrawn	0	UCB Biopharma SRL	Jun 2021
NCT04646187	FREE	De-escalation of Anti-TNF Therapy in Inflammatory Bowel Disease	P4	enrolling by invitation	148	University Medical Center Groningen	Mar 2021
NCT02706704	IVAS	Intravitreal Adalimumab Versus Subcutaneous Adalimumab in Non-infectious Uveitis	P2	recruiting	32	American University of Beirut Medical Center	Feb 2016
NCT05151848	ADATOFTAK	Comparison of Adalimumab and Tofacitinib in the Treatment of Active Takayasu Arteritis	P4	unknown	100	Chinese SLE Treatment And Research Group	Jan 2022
NCT06005532		Study Evaluation of the Efficacy, Safety and Immunogenicity of Adalimumab in Comparison With Humira®	P3	unknown	494	Mabscale, LLC	Oct 2023
NCT05313620		Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events	P4	recruiting	30	Fundación de Investigación Biomédica - Hospital Universitario de La Princesa	Apr 2022
NCT07181694		A Study of Pharmacokinetics, Safety, and Immunogenicity of BCD-057 100 mg/mL, BCD-057 50 mg/mL, and Humira 100 mg/mL in Healthy Subjects	P1	recruiting	444	Biocad	Mar 2025
NCT05502731	JAKAR	Januse Kinase Inhibition With Filgotinib to Silence Autoreactive B Cells in Rheumatoid Arthritis	P4	unknown	40	Leiden University Medical Center	Oct 2022
NCT04610476		Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis	P3	unknown	270	University of Erlangen-Nürnberg Medical School	Oct 2020
NCT04798755	Co-THEIA	Efficacy, Safety and Costs of Methotrexate, Adalimumab, or Their Combination in Non-infectious Non-anterior Uveitis	P3	unknown	192	Hospital San Carlos, Madrid	Jan 2022
NCT06527534	FILRA	Filgotinib Effect on Proteomic Profile and Micro-RNA Expression in Patients With Active Rheumatoid Arthritis (RA)	P4	recruiting	30	Universita di Verona	Jul 2024
NCT05913817	EASE PAIN	The Evaluation of Injection Site Pain and Adherence in Patients Switching From a Low To High Concentration Adalimumab (AVT-02) Across Multiple Indications.	—	completed	324	Jamp Pharma Corporation	Jan 2023
NCT06117423	GUIDE	Fluorescence Imaging of Adalimumab-680LT in Inflammatory Bowel Disease	P1/P2	unknown	21	University Medical Center Groningen	Mar 2024
NCT06242652	AS	A Study to Evaluate 608 in Patients with Ankylosing Spondylitis (AS)	P2	unknown	250	Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.	Mar 2024
NCT06370156		Evaluation of TWEAK in Plaque Psoriasis and Psoriatic Arthritis Patients	—	unknown	100	Egymedicalpedia	Jun 2024
NCT03261102		TDM Guided Early Optimization of ADAL in Crohn's Disease	N/A	active not recruiting	200	waqqas.afif	Jan 2017
NCT02632175		Long-term Safety and Efficacy Study of Adalimumab in Pediatric Subjects With Ulcerative Colitis	P3	completed	59	AbbVie	Nov 2015
NCT03816397	ADJUST	Adalimumab in JIA-associated Uveitis Stopping Trial	P4	completed	87	Nisha Acharya	Mar 2020
NCT03306446	CURE	Changing the coUrse of cRohn's Disease With an Early Use of Adalimumab	P4	unknown	203	Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives	Mar 2015
NCT05527444		The Clinical Efficacy and the Changes of Immune Cells Subsets With Bioagents in Ankylosing Spondylitis Patients	P4	unknown	100	Qilu Hospital of Shandong University	Mar 2022
NCT04194827	ADDORA	Adalimumab Drug Optimisation in Rheumatoid Arthritis Using Therapeutic Drug Monitoring	P4	unknown	267	Reade Rheumatology Research Institute	Mar 2020
NCT03885713	BioIBD	Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease	P4	completed	180	Fundación de Investigación Biomédica - Hospital Universitario de La Princesa	Sep 2019
NCT05590416		A Study of Adalimumab in Acute Vogt-Koyanagi-Harada Disease	—	recruiting	15	Tianjin Medical University	Jun 2021
NCT05090124	REALISE	Experimental Medicine Studies of the Brain in Patients With Rheumatoid Arthritis REALISE	N/A	completed	46	NHS Greater Glasgow and Clyde	Nov 2022
NCT05164198	RECAST	REduCed Dose of TNFi in Patients With Ankylosing SpondyliTis (RECAST)	P4	unknown	448	Hanyang University Seoul Hospital	Jan 2022
NCT03739853	SPEED	Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED Trial	P4	completed	192	University of Oxford	May 2019
NCT06269185		Comparison Between Infliximab and Adalimumab on Patients With Ulcerative Colitis	—	completed	271	Vastra Gotaland Region	Mar 2024
NCT03828019	ADVISE	Adalimumab vs. Conventional Immunosuppression for Uveitis Trial	P3	completed	227	JHSPH Center for Clinical Trials	Sep 2019
NCT03104400	SELECT - PsA 1	A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)	P3	completed	1,705	AbbVie	Apr 2017
NCT01793519	STARA	Stopping TNF Alpha Inhibitors in Rheumatoid Arthritis	P4	unknown	290	Georgetown University	Jan 2013
NCT07113834	uveitis	Characteristics of Ankylosing Spondylitis Associated Uveitis	—	completed	22	Benha University	Sep 2023
NCT06033469		Therapeutic Monitoring of Infliximab and Adalimumab	—	unknown	100	IRCCS Burlo Garofolo	Mar 2018
NCT05414201		A Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Participants Requiring High Dose Corticosteroids for Active Non-Infectious Intermediate, Posterior, or Pan-Uveitis	P4	completed	87	AbbVie	Jul 2022
NCT02586831	DIPIT	Diabetes Islet Preservation Immune Treatment	P1/P2	withdrawn	0	Camillo Ricordi and Jay Skyler	Jun 2024
NCT02332356		Therapeutic Optimization Study Based on MR Enterocolonography in Patients With Crohn's Disease	P3	unknown	100	Tokyo Medical and Dental University	Sep 2014
NCT00783510	STRIVE	Juvenile Idiopathic Arthritis (JIA) Registry	—	completed	849	AbbVie	Jul 2008
NCT05889338		Effect of Adalimumab Therapy on Psoriasis Patient	N/A	unknown	140	Sohag University	Jun 2023
NCT05640245		Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis	P2	completed	207	MoonLake Immunotherapeutics AG	Dec 2022
NCT04300686		A Pilot Study in Severe Patients With Takayasu Arteritis.	P4	recruiting	40	Shanghai Zhongshan Hospital	Mar 2020
NCT04588818		Adalimumab Plus Methotrexate for the Treatment of Pediatric Uveitis	P2	unknown	30	Sun Yat-sen University	Feb 2020
NCT04131504	ENvISION	Precision Crohn's Disease Management Utilizing Predictive Protein Panels (ENvISION)	—	completed	239	Children's Hospital Medical Center, Cincinnati	Oct 2019
NCT06291948		A Clinical Study With Adalimumab Biosimilar	P1	completed	150	Laboratorios Richmond S.A.C.I.F.	Aug 2022
NCT04009668		Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease	P2	completed	7	University of Michigan	Oct 2019
NCT06600009	FLYWAY	Treatment Persistence of Biologics in Patients with PsA in Japan; Retrospective Cohort Study Using a Claims Database	—	completed	534	Novartis	Oct 2022
NCT04222920	ADDORA-low	Adalimumab Dose Reduction Aiming Low Serum Concentration With Control of Disease Activity	P4	completed	78	Reade Rheumatology Research Institute	Mar 2020
NCT04655807	DUET	A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease	P2	withdrawn	0	Janssen Research & Development, LLC	Mar 2021
NCT05322473		Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa	P2	completed	234	MoonLake Immunotherapeutics AG	Apr 2022
NCT05884242		A Study of Adalimumab on Inflammatory Mediators Following a Systemic Endotoxin Challenge	P1	completed	20	Janssen Research & Development, LLC	May 2023
NCT05015335		The Efficacy and Safety of Adalimumab in Non-infectious Anterior Pediatric Uveitis With Peripheral Vascular Leakage	P4	unknown	50	Peking Union Medical College Hospital	Aug 2021
NCT05153200		Early Changes in Pain, Disease Activity, and Ultrasound Evidence of Inflammatory Synovitis in Patients Receiving JAK-inhibitor vs. TNF-inhibitor Therapy for Active Rheumatoid Arthritis: A Feasibility Study.	P4	unknown	40	Ottawa Hospital Research Institute	Jan 2022
NCT05299242	Anti-FreazeF	The Anti-Freaze-F Study- "Anti-TNF for Treatment of Frozen Shoulder - a Feasibility Study"	P2/P3	completed	9	University of Oxford	Jul 2022
NCT05510063		Pharmacokinetics, Efficacy, Safety, and Immunogenicity of SB5 Versus Humira in Subjects With Moderate to Severe Chronic Plaque Psoriasis	P4	completed	371	Samsung Bioepis Co., Ltd.	Aug 2022
NCT05291039		Infliximab and Adalimumab in Inflammatory Bowel Disease Patients.	N/A	completed	56	Rehab Werida	Jan 2022
NCT05155592		Reduction or Discontinuation of TNF-α Inhibitor in Non-infectious Uveitis Patients	P2	unknown	28	Dan Liang	Jan 2021
NCT05427942	YU-MATTER	Yuflyma® (Adalimumab), Patient Experience After Switching	—	unknown	300	Celltrion HealthCare France	Jun 2022
NCT04882683		Clinical Study of Cord Blood Mononuclear Cells on Treatment of Hormone-resistant or Hormone-dependent Ulcerative Colitis	N/A	unknown	50	Shandong Qilu Stem Cells Engineering Co., Ltd.	Jun 2021
NCT03927352		The Purpose of This Research Study is to Compare the Efficacy and Safety of SCT630 and Adalimumab (HUMIRA®) in Adults With Plaque Psoriasis	P3	unknown	330	Sinocelltech Ltd.	Sep 2019
NCT02994836		GIS-SUSANTI-TNF-2015 (Anti-TNF Discontinuation )	P4	completed	139	Fundación de Investigación Biomédica - Hospital Universitario de La Princesa	Apr 2017
NCT05073315		A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis	P3	completed	425	Amgen	Oct 2021
NCT04988308	LYRA	A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa	P2	terminated	151	Janssen Research & Development, LLC	Oct 2021
NCT05706038	COV-ADA	Impact of Adalimumab Withdrawal or Continuation on Severity of COVID-19 and Risk of IMID Relapse	—	completed	49	IRCCS San Raffaele	Apr 2022
NCT05172817	ACT	Study to Compare PK & Safety of Advixa With Humira in Healthy, Adult Subject Followed by Efficacy & Safety Study in RA Patients	P2/P3	unknown	200	Institute for Developing Science and Health Initiatives, Bangladesh	Jun 2021
NCT04255134	BIORA-PAIN	Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)	P4	completed	18	St George's, University of London	Sep 2020
NCT05379049	TNF-alpha	Therapeutic Response to Tumor Necrosis Factor-alpha (TNF-alpha) Antagonists in Rheumatoid Arthritis.	—	unknown	80	University of Sulaimani	Mar 2022
NCT04705844	COMBAAT	Study of Adalimumab or Placebo in Patients With Mild to Moderate COVID-19 (COMBAAT)	P3	withdrawn	0	Alachua Government Services, Inc.	Sep 2021
NCT03906136	AScalate	AScalate: Treat-to-target in Axial Spondyloarthritis	P3	completed	304	Novartis Pharmaceuticals	Jun 2019
NCT04132388		Hidradenitis Suppurativa Patient Experience With Humira Treatment	P4	withdrawn	0	Wake Forest University Health Sciences	Aug 2020
NCT05530122	biological	Prognosis in UC After First Biological	—	completed	192	Tampere University Hospital	Jan 2009
NCT05683054		A Non-inferiority Study on Dose Reduction of Adalimumab in Psoriasis Patients Who Are Overtreated	P4	completed	19	University Hospital, Ghent	Aug 2020
NCT03221621	HS-COST	Cost-effectiveness of Adalimumab and Surgery vs Adalimumab in HS	P4	unknown	128	Erasmus Medical Center	Jul 2018
NCT04551352	TYRP1	A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas	P1	completed	20	Hoffmann-La Roche	Oct 2020
NCT05372939	MARKET	Study of the Efficacy and Safety of AMT-101 in Combination With Adalimumab in Subjects With Ulcerative Colitis (MARKET)	P2	completed	51	Applied Molecular Transport	Feb 2021
NCT03895203	BE OPTIMAL	A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis	P3	completed	852	UCB Biopharma SRL	Apr 2019
NCT02764762	CD	Triple Combination Therapy in High Risk Crohn's Disease (CD)	P4	completed	55	Takeda	Apr 2017
NCT03662919	PERFUSE	One-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi: a French Cohort Study	—	completed	2,274	Biogen	Jul 2018
NCT02929251	RUBI	Randomized Trial Comparing Efficacy of Adalimumab, Anakinra and Tocilizumab in Non-infectious Refractory Uveitis	P2	completed	112	Assistance Publique - Hôpitaux de Paris	Jun 2017
NCT03100253	RAFTING	Rheumatoid Arthritis Treatment After First Anti-TNF INvestiGation	P4	terminated	208	Mario Negri Institute for Pharmacological Research	Mar 2018
NCT04089514	PROPER	A Real-world Study of Imraldi® Use	—	completed	1,000	Biogen	Jun 2019
NCT03259074	SURPASS	Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar)	P3	completed	859	Novartis Pharmaceuticals	Nov 2017
NCT04453137		Pharmacokinetic, Efficacy, Safety, and Immunogenicity of AVT02 With Moderate to Severe Chronic Plaque Psoriasis	P3	completed	567	Alvotech Swiss AG	Jun 2020
NCT04404517	IntnsificADA	Correlation of Serum Adalimumab Levels at an Administration of 40 mg Weekly vs 80 mg Every Two Weeks	P3	unknown	20	Hospital Universitario La Paz	Oct 2019
NCT04115423		A Retrospective Cohort Study on the Risk of Serious Infections in Rheumatoid Arthritis Patients Receiving Tocilizumab	—	unknown	9,508	Sungkyunkwan University	Apr 2020
NCT03220841	STRIDENT	Stricture Definition and Treatment (STRIDENT) Drug Therapy Study	P4	unknown	78	St Vincent's Hospital Melbourne	Oct 2017
NCT03619876	AMiRA	Effects of Abatacept on Myocarditis in Rheumatoid Arthritis	P4	terminated	11	Columbia University	Jul 2019
NCT03955861		Ultrasound Enthesitis Response in Psoriatic Arthritis	—	completed	80	Belfast Health and Social Care Trust	Feb 2019
NCT04230213		A Comparative Study Between PF-06410293 and Humira® in Combination With Methotrexate in Participants With Active Rheumatoid Arthritis	P3	completed	455	Pfizer	Jan 2020
NCT02852694	RCT	Reduce Risk for Crohn's Disease Patients	P4	completed	192	PIBD-Net	Feb 2017
NCT02374021	TARGET	Treatments Against RA and Effect on FDG-PET/CT	P4	completed	159	Brigham and Women's Hospital	Jul 2016
NCT03464136	SEAVUE	Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year	P3	completed	386	Janssen Scientific Affairs, LLC	Mar 2018
NCT04514796		Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Two Formulations of SB5 in Healthy Male Subjects	P1	completed	188	Samsung Bioepis Co., Ltd.	Aug 2020
NCT04115748	PENGUIN 1	Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy	P3	terminated	67	Gilead Sciences	Dec 2019
NCT03505008		Evaluation of the Optimal MTX Dose as an Add-on Therapy to Adalimumab for RA Patients in Japan, South Korea and Taiwan	P4	completed	300	Keio University	Apr 2018
NCT02471118	OKINADA	Osteoarthritis of the Knee, Inflammation, and the Effect of Adalimumab (OKINADA)	P2	completed	62	CARE ARTHRITIS LTD.	Mar 2015
NCT04808739		Adalimumab Biosimilar in Clinical Practice	—	completed	604	Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau	Jun 2020
NCT04224194		Auto-injector Real Life Handling in Patients	P3	completed	107	Alvotech Swiss AG	Nov 2019
NCT02878083	DETECT	Development of a Biomarker of Efficacy of Vedolizumab (EnTyvio®) in Patients With ulcErative ColiTis (DETECT)	N/A	terminated	19	Nantes University Hospital	Jan 2017
NCT03180957	RIDD	Repurposing Anti-TNF for Treating Dupuytren's Disease	P2	completed	140	University of Oxford	Mar 2016
NCT02332590	SARIL-RA-MONARCH	Efficacy and Safety of Sarilumab and Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (SARIL-RA-MONARCH)	P3	completed	369	Sanofi	Jan 2015
NCT01602302	RA-BioStop	Ultrasound and Withdrawal of Biological DMARDs in Rheumatoid Arthritis	P4	terminated	40	Medical University of Graz	Jun 2012
NCT02840175	AJIBIOREM	Treatment Tapering in JIA With Inactive Disease	P3	completed	62	Assistance Publique - Hôpitaux de Paris	May 2017
NCT03823391	RA	A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Participants With Moderate to Severe Rheumatoid Arthritis (RA)	P2	completed	48	AbbVie	Mar 2019
NCT02092467	TNF	Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis	P4	completed	4,372	Pfizer	Mar 2014
NCT03849404		Efficacy, Safety, and Immunogenicity of AVT02 With Moderate-to-Severe Chronic Plaque Psoriasis	P3	completed	413	Alvotech Swiss AG	Feb 2019
NCT02207244	VOYAGE 2	A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment	P3	completed	992	Janssen Research & Development, LLC	Nov 2014
NCT02207231	VOYAGE 1	A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis	P3	completed	837	Janssen Research & Development, LLC	Nov 2014
NCT03737708	RA	A Study Comparing Biologics + Methotrexate With Biologics + Tacrolimus in Patients With Rheumatoid Arthritis (RA)	P4	completed	21	Astellas Pharma Korea, Inc.	Feb 2019
NCT02171429	HIBISCUS II	A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors	P3	completed	358	Hoffmann-La Roche	Nov 2014
NCT03561649	PRESHUM	Prediction of Treatment Response at 6 Months by Combinatorial Analysis of Serum Biomarkers in Biotherapy Naive SpA	N/A	completed	50	University Hospital, Grenoble	Jun 2018
NCT04171414		A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis	P3	completed	62	Celltrion	Sep 2019
NCT03311464		A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in Japan	P3	completed	22	AbbVie	Oct 2017
NCT02814175	CONTROL	A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)	P4	completed	246	AbbVie	Aug 2016
NCT02163759	HIBISCUS I	A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors	P3	completed	358	Hoffmann-La Roche	Nov 2014
NCT03412747	BE SURE	A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis	P3	completed	478	UCB Biopharma SRL	Jan 2018
NCT03849313		Pharmacokinetics, Safety and Tolerability Study of AVT02 to EU-approved and US-licensed Humira (Adalimumab)	P1	completed	390	Alvotech Swiss AG	Mar 2019
NCT02065557		Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis	P3	completed	101	AbbVie	Oct 2014
NCT02065570		Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease	P3	completed	514	AbbVie	May 2014
NCT04439929		Comparative Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of Adalimumab in Healthy Subjects	P1	completed	168	Turgut İlaçları A.Ş.	Jul 2019
NCT02878161		Predictability Studies on the Efficacy of TNF-α Inhibitors in Chinese RA From "Real World"	P4	unknown	240	Fen Li	Jan 2016
NCT02035800	BROCAII	Bone Resorption, Osteoclastogenesis and Adalimumab	P4	unknown	120	Université de Sherbrooke	May 2013
NCT02745080	EXCEED 1	Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis	P3	completed	853	Novartis Pharmaceuticals	Apr 2017
NCT03016260	RABIOPRED	RABIOPRED - a Validation Study of Theranostic Test to PREDict Treatment Response of Anti-TNFα BIologicals in Rheumatoid Arthritis	—	terminated	250	TcLand Expression S.A.	Dec 2016
NCT03983876	PFS	PK, Safety and Tolerability Study of AVT02 (Adalimumab) Pre-filled Syringe (PFS) vs, AVT02 Autoinjector (AI)	P1	completed	207	Alvotech Swiss AG	Jul 2019
NCT02065622		Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis	P3	completed	952	AbbVie	Mar 2014
NCT02760407	CREDO 2	Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease	P3	completed	1,648	R-Pharm International, LLC	Jun 2016
NCT03917628		Pharmacokinetics and Safety in Healthy Volunteers	P1	completed	146	Sinocelltech Ltd.	May 2019
NCT02808975	SHARPS	Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically	P4	completed	206	AbbVie	Jul 2016
NCT03151551	SPIRIT-H2H	A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis	P4	completed	566	Eli Lilly and Company	Aug 2017
NCT03059849	BEAT-IBD	Brief Escalation of Adalimumab Treatment for Prevention of Clinical Relapse in IBD	P4	withdrawn	0	McMaster University	Feb 2018
NCT02056184	TURA	Targeted Ultrasound in Rheumatoid Arthritis	P4	completed	183	University of Leeds	Dec 2013
NCT02889796	FINCH 1	Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate	P3	completed	1,759	Gilead Sciences	Aug 2016
NCT02904902		Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa	P3	completed	15	AbbVie	Sep 2016
NCT03316781		Study of Efficacy and Safety of HLX03 in Subjects With Moderate to Severe Plaque Psoriasis	P3	completed	262	Shanghai Henlius Biotech	Oct 2017
NCT02557100		Study to Assess Changes in the Immune Profile in Adults With Early Rheumatoid Arthritis	P4	completed	80	Bristol-Myers Squibb	Nov 2015
NCT03248531		A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa.	P2	completed	90	UCB Biopharma SRL	Sep 2017
NCT02256462	PAILOT	Pediatric Crohn's Disease AdalImumab Level-based Optimization Treatment (PAILOT) Trial	P4	completed	82	Schneider Children's Medical Center, Israel	May 2015
NCT02497469	IV	An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis	P3	completed	771	Takeda	Jun 2015
NCT03217734	MAP	MAP Study: Methotrexate and Adalimumab in Psoriasis	P2/P3	completed	56	Jeffrey J Crowley MD	Apr 2017
NCT03607903		Adalimumab Microneedles in Healthy Volunteers	P1/P2	completed	24	Centre for Human Drug Research, Netherlands	Jul 2018
NCT01610947	SPACING	Effect of Spacing of Anti-TNF Drugs in Ankylosing Spondylitis With Low Disease Activity	N/A	completed	398	University Hospital, Montpellier	May 2012
NCT02696785	COAST-V	A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis	P3	completed	341	Eli Lilly and Company	May 2016
NCT02963402		Immunoregulatory Mechanisms of Treg Cells Induced by Tocilizumab	—	completed	35	Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau	Nov 2016
NCT03357939		Phase I Study of HLX3 vs Adalimumab in Chinese Healthy Subjects	P1	completed	220	Shanghai Henlius Biotech	Jan 2017
NCT03579823	ALVOPAD	Comparative Safety, Tolerability, Pharmacokinetic Study of AVT02 (100MG/ML) and Humira (100MG/ML) in Healthy Volunteers	P1	completed	24	Alvotech Swiss AG	May 2018
NCT02668640		Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in China	—	completed	55	AbbVie	May 2016
NCT02198651	PREDICTRA	A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects	P4	completed	149	AbbVie	Jan 2015
NCT03254810		Comparison of the Safety and PK of SYN060 to Humira® in Healthy Adult Subjects	P1	completed	94	Synermore Biologics Co., Ltd.	Sep 2017
NCT02833350	RA	Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)	P2	completed	578	Genentech, Inc.	Sep 2016
NCT01986127		Adalimumab Intralesional in Intestinal Strictures of Crohn's Disease Patients	P3	terminated	26	Sara Varea	Feb 2014
NCT01387815	Complete-PS	Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Psoriasis	—	completed	662	AbbVie (prior sponsor, Abbott)	Aug 2011
NCT03043677		Ex-vivo Modulatory Effect of Biological Drugs for Inflammatory Bowel Disease on the Mucosa and on Peripheral Blood Mononuclear Cells	—	completed	45	Fundación de Investigación Biomédica - Hospital Universitario de La Princesa	Apr 2016
NCT02492217	TNF	Biomarkers Identification of Anti-tumor Necrosis Factor (TNF) α Agent's Efficacy in Ankylosing Spondylitis Patients	P4	completed	69	Universidade Nova de Lisboa	May 2015
NCT01148225	VISUAL III	A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis	P3	completed	424	AbbVie	Nov 2010
NCT01870284	SPIRIT A1	Study of Ixekizumab in Participants With Active Ankylosing Spondylitis (AS)	P3	withdrawn	0	Eli Lilly and Company	Jul 2014
NCT01736189		Assessment of Clinical Effectiveness and Safety of Adalimumab and High Dose Methotrexate in Routine Clinical Practice	—	completed	346	AbbVie (prior sponsor, Abbott)	Oct 2012
NCT02750800	VALUE	Post-marketing Observational Study to Evaluate the Incremental Impact of AbbVie's Patient Support Program on Patient Reported Outcomes and Health Resource Utilization in Inflammatory Arthritis, Psoriasis and Inflammatory Bowel Diseases in Hungary (VALUE)	—	completed	427	AbbVie	Apr 2016
NCT02739828	HOPE	Post Marketing Observational Study (PMOS) to Assess Quality of Life in Swedish Hidradenitis Suppurativa (HS) Patients	—	completed	24	AbbVie	Apr 2016
NCT02893254		Efficacy and Safety of IBI303 in Adult Patients With Active Ankylosing Spondylitis	P3	completed	438	Innovent Biologics (Suzhou) Co. Ltd.	Sep 2016
NCT02634541	PETSPA	Adalimumab in Alleviating Inflammation in Patients With Axial Spondyloarthritis	P4	unknown	60	University of Helsinki	Jan 2016
NCT02897115	STRIKE	A Study Treating Participants With Early Axial Spondyloarthritis (axSpA) Taking an Intense Treatment Approach Versus Routine Treatment	P4	terminated	22	AbbVie	Sep 2016
NCT02539849		Effect of Prebiotic FOS on Intestinal Abundance of Faecalibacterium Prausnitzii in Patients With Crohn´s Disease	N/A	completed	38	Hospital Universitari Vall d'Hebron Research Institute	Dec 2014
NCT02499783		Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects With Moderate to Severe Crohn's Disease	P3	completed	205	AbbVie	Aug 2015
NCT02480153	REFLECTIONS B538-02	A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira®) In Combination With Methotrexate In Subjects With Active Rheumatoid Arthritis (REFLECTIONS B538-02).	P3	completed	597	Pfizer	Jun 2015
NCT02185014		Open Label Study to Evaluate Long Term Efficacy, Safety and Tolerability of Repeated Dosing in Subjects With Crohn's Disease and Who Participated and Successfully Completed M14-115	P3	completed	252	AbbVie	Aug 2014
NCT01695239	SPIRIT-P1	A Study of Ixekizumab in Participants With Active Psoriatic Arthritis	P3	completed	417	Eli Lilly and Company	Dec 2012
NCT01609205	Muscara	Doppler Evaluation in RA Patients After Adalimumab.	P4	completed	60	Hamed Rezaei	Oct 2012
NCT02744755	ADMYRA	Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis	P3	completed	353	Sandoz	Mar 2016
NCT02912247		Comparative Clinical Trial to Evaluate Bioequivalency and Safety of Monoclonal Antibody Injection and Adalimumab in Chinese Healthy Volunteers	P1	completed	183	Innovent Biologics (Suzhou) Co. Ltd.	Oct 2016
NCT02113904	AntiTNF-SN	Clinical Trial Using Humira in Netherton Syndrome	P2	completed	11	Assistance Publique - Hôpitaux de Paris	Jan 2014
NCT02150473	MTX	The Effect of Adalimumab Plus Methotrexate (MTX) Versus Placebo Plus MTX on Cartilage in (RA) Patients	P3	terminated	21	Heinrich-Heine University, Duesseldorf	Oct 2014
NCT02694523		BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis	P3	completed	684	AbbVie	Mar 2016
NCT01768858	Adherence	Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice	—	completed	96	AbbVie	Feb 2013
NCT02333383	AS PMOS	Observe the Frequency of Extra-Axial Symptoms in Korean Ankylosing Spondylitis (AS) Patients	—	completed	201	AbbVie	Dec 2014
NCT03273192		A Study Of CinnoRA (Adalimumab-CinnaGen) And Adalimumab (Humira) In Healthy Subjects	P1	completed	74	Cinnagen	Oct 2016
NCT01893996		Study of Adalimumab to Lower Cardiovascular Risk in RA Patients With Well Controlled Joint Disease	P4	completed	63	Jonathan Graf	Jul 2013
NCT02533375	GPP	Study to Investigate Efficacy and Safety of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)	P3	completed	10	AbbVie	Sep 2015
NCT00932113	MOA	Mechanism of Action Study for Psoriasis	P4	completed	33	Tufts Medical Center	Jun 2009
NCT01808118		Continuing Versus Withdrawing Adalimumab in Maintaining Remission in Non-Radiographic Axial Spondyloarthritis	P3	completed	673	AbbVie	Apr 2013
NCT00686374		Efficacy and Long Term Safety of Adalimumab in Pediatric Subjects Who Have Demonstrated Clinical Response in M06-806	P3	completed	100	AbbVie (prior sponsor, Abbott)	May 2008
NCT02489227	PsOsim	Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis	P3	completed	545	Coherus Oncology, Inc.	Aug 2015
NCT02714322		MYL-1401A Efficacy and Safety Comparability Study to Humira®	P3	completed	294	Mylan Inc.	Jun 2015
NCT02196701	CLEAR	Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real World: the CLEAR Study	P3	completed	46	AbbVie	Aug 2014
NCT00480272	CURE	Prospective Study on Intensive Early Rheumatoid Arthritis Treatment	P4	completed	251	Fondazione IRCCS Policlinico San Matteo di Pavia	May 2007
NCT02148718	RAPIDA	Rapidity of Response to Adalimumab Treatment in Patients With Crohn´s Disease	P4	completed	100	AbbVie	Jun 2014
NCT01971970	IBD	Biomarkers of Anti-TNF Treatment in Inflammatory Bowel Disease (IBD)	—	completed	45	Erasmus Medical Center	Oct 2013
NCT02927353	DMB-3113-1	A Phase 1 Pharmacokinetic Bioequivalence Study of DMB-3113 and Adalimumab in Healthy Japanese Adult Male Subjects	P1	completed	180	Meiji Seika Pharma Co., Ltd.	Aug 2016
NCT04154852	ADEOS	ADalimumab in Persistent Early Oligoarthrits Study (ADEOS)	P2	completed	22	University of Leeds	Jun 2011
NCT03172325		Study to Demonstrate Non-Inferior Efficacy and Safety of CinnoRA® Versus Humira® for Treatment of Active RA	P3	completed	136	Cinnagen	Nov 2015
NCT01235689	CALM	Efficacy and Safety of Two Treatment Algorithms in Adults With Moderate to Severe Crohn's Disease	P3	completed	252	AbbVie (prior sponsor, Abbott)	Feb 2011
NCT02187055	ORAL STRATEGY	An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate	P4	completed	1,152	Pfizer	Aug 2014
NCT02330380		Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation	—	completed	26	University Hospitals Cleveland Medical Center	Apr 2013
NCT00573794		Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis	P3	completed	592	AbbVie (prior sponsor, Abbott)	Nov 2007
NCT02073526		Anti-TNF-alpha Trough Level Measurements in Inflammatory Bowel Disease	—	completed	1,230	Oslo University Hospital	May 2013
NCT01197144	PARADE	Pain Modulation in Rheumatoid Arthritis (RA) - Influence of Adalimumab	N/A	completed	70	Karolinska Institutet	Oct 2010
NCT02393378	TELLUS	Namilumab vs Adalimumab in Participants With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to Methotrexate	P2	terminated	7	Takeda	Apr 2015
NCT01497717		Efficacy of Humira in Behcet Patients With Arthritis	P3	completed	9	Rambam Health Care Campus	Jul 2013
NCT02489760		Etanercept Versus Adalimumab in the Treatment of Patients With Ankylosing Spondylitis. A Switch Study	P4	unknown	30	Chung Shan Medical University	Jul 2008
NCT01866592	VIP-E	Vascular Inflammation in Psoriasis - Extension Study	P4	completed	81	University of Pennsylvania	Apr 2013
NCT01553058	VIP	Vascular Inflammation in Psoriasis Trial (The VIP Trial)	P4	completed	97	University of Pennsylvania	Jul 2012
NCT01635764	PIONEER (OLE)	Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of Hidradenitis Suppurativa	P3	completed	508	AbbVie (prior sponsor, Abbott)	Apr 2012
NCT02019472	SIRROUND-H	A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis	P3	completed	559	Janssen Research & Development, LLC	Apr 2014
NCT02437253		Effects of Adalimumab in Mucopolysaccharidosis Types I, II and VI	P1/P2	completed	2	Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center	May 2015
NCT01629628	POPART	Adalimumab for the Management of Post-operative Crohn's Disease (CD)	P3	unknown	100	Tel-Aviv Sourasky Medical Center	Jul 2012
NCT01716039	UC	Pharmacokinetics of Adalimumab With Methotrexate for Treatment of Patients With Ulcerative Colitis (UC)	P2	terminated	22	Alimentiv Inc.	Jun 2013
NCT02349451	MTX	A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects With Active Psoriatic Arthritis (PsA) Who Have an Inadequate Response to Methotrexate (MTX)	P2	completed	240	AbbVie	Apr 2015
NCT02450513		Adalimumab Trough Concentrations in Crohn's Disease: A Pilot Pharmacokinetic Study	—	completed	30	Universitaire Ziekenhuizen KU Leuven	Mar 2012
NCT02016482		A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis	P3	completed	217	AbbVie	Jan 2014
NCT01556672		Adalimumab-psoriasis and Small Bowel Lesions	P4	completed	100	Innovaderm Research Inc.	Apr 2012
NCT02565810		An Multicentre Clinical Study to Evaluate the Usability and Safety of the Pre-filled Pen and Pre-filled Syringe of SB5 in Subjects With Rheumatoid Arthritis	P2	completed	49	Samsung Bioepis Co., Ltd.	Sep 2015
NCT01674413	CADHUM	Calprotectin-Directed Humira® Maintenance Therapy (CADHUM)	P3	withdrawn	0	Peter Higgins	Oct 2013
NCT02016105	ADACCESS	Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and Humira	P3	completed	465	Sandoz	Dec 2013
NCT01722214		Trial on the Effect of Adalimumab on Vascular Inflammation in Patients With Psoriasis	P4	completed	107	Innovaderm Research Inc.	Nov 2012
NCT01670240	ADAP	Adalimumab in the Treatment of Chronic Pouchitis	P3	completed	13	Odense University Hospital	Aug 2012
NCT01500278	RA	Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate	P4	completed	915	UCB Pharma SA	Dec 2011
NCT02516774	TAM-RT	A Trial of Adalimumab Combined to Chemotherapy and Radiotherapy in Patients With Anaplastic Thyroid Cancers	P1	withdrawn	0	Gustave Roussy, Cancer Campus, Grand Paris	Dec 2014
NCT01166282		A Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Enthesitis Related Arthritis	P3	completed	46	AbbVie (prior sponsor, Abbott)	Sep 2010
NCT00517296	EUS	Endoscopic Ultrasound (EUS) Guided Treatment With Humira for Crohn's Perianal Fistulas	P4	completed	21	Vanderbilt University Medical Center	Jan 2008
NCT01877668	OPAL BROADEN	Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study	P3	completed	422	Pfizer	Jan 2014
NCT05995691	PK	Study to Determine the Pharmacokinetic (PK) Bioequivalence of ABP 501 and Adalimumab (Humira®) in Healthy Adult Japanese Participants	P1	completed	179	Amgen	Nov 2014
NCT02141997		A Study to Investigate the Safety and Efficacy of ABT-122 Given With Methotrexate in Subjects With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate	P2	completed	222	AbbVie	Jul 2014
NCT01295151	SWITCH	SWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug.	P4	completed	122	Julia Brown	Aug 2011
NCT02395055		Comparative Clinical Study of Pharmacokinetics, Tolerance and Safety of BCD-057 and Humira in Healthy Volunteers	P1	completed	94	Biocad	Jun 2015
NCT02167139		A Study Comparing SB5 to Humira® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy	P3	completed	544	Samsung Bioepis Co., Ltd.	May 2014
NCT01958827		A Study of Adalimumab After Dose Escalation in Japanese Subjects With Crohn's Disease	P3	completed	28	AbbVie	Sep 2013
NCT02097264		A Trial Investigating the Mechanism of Action of NNC0109-0012 (Anti-IL-20 mAb) Through Synovial Biopsies in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate	P2	withdrawn	0	Novo Nordisk A/S	Sep 2014
NCT01710358	RA-BEAM	A Study in Moderate to Severe Rheumatoid Arthritis	P3	completed	1,307	Eli Lilly and Company	Oct 2012
NCT01162421	RADAR	A Canadian Study to Evaluate Early Use of Adalimumab After Methotrexate Failure in Early Rheumatoid Arthritis	P4	completed	77	AbbVie (prior sponsor, Abbott)	Sep 2010
NCT01373151		Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate	P2	completed	418	CSL Behring	Jun 2011
NCT01124838	Visual II	Efficacy and Safety of Adalimumab in Subjects With Inactive Uveitis	P3	completed	261	AbbVie (prior sponsor, Abbott)	Aug 2010
NCT01550965	InspirAda	A Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Utilization and Costs of Ulcerative Colitis Subjects in the Usual Clinical Practice Setting	P3	completed	463	AbbVie (prior sponsor, Abbott)	May 2012
NCT01021735	ORBIT	Optimal Management of Rheumatoid Arthritis Patients Requiring Biologic Therapy	P4	completed	302	University of Glasgow	Apr 2010
NCT01895764	COMARIS	Effect of the Combination of Methotrexate and Adalimumab on Reduction of Immunization in Ankylosing Spondylitis (COMARIS)	P4	completed	110	University Hospital, Tours	Mar 2013
NCT02237729	B538-07	A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira) In Healthy Subjects (REFLECTIONS B538-07))	P1	completed	362	Pfizer	Sep 2014
NCT01320293		Cardiovascular Effects in Psoriasis Patients Treated With Adalimumab.	N/A	completed	18	University of North Carolina, Chapel Hill	Mar 2011
NCT01970488		Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (HUMIRA®) in Adults With Moderate to Severe Plaque Psoriasis	P3	completed	350	Amgen	Oct 2013
NCT02015793		Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Two Treatment Modules in Chinese Subjects With Moderate to Severe Crohn's Disease	P2	completed	30	AbbVie	Dec 2013
NCT01251614		A Double Blind Study in Pediatric Subjects With Chronic Plaque Psoriasis, Studying Adalimumab vs. Methotrexate	P3	completed	114	AbbVie (prior sponsor, Abbott)	Dec 2010
NCT01764997	RA-COMPARE	An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate	P3	terminated	776	Sanofi	Apr 2013
NCT01564823	APPRECIA	Adalimumab on Preventing Post-chirurgic Recurrence on Crohn´s Disease	P3	completed	86	Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa	Jun 2012
NCT01592292		An Observational Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis And Inadequate Response Or Intolerance to a First Anti-TNF Alpha Therapy	—	completed	90	Hoffmann-La Roche	Nov 2011
NCT01970475		Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis	P3	completed	526	Amgen	Oct 2013
NCT01138657	VISUAL l	Efficacy and Safety of Adalimumab in Patients With Active Uveitis	P3	completed	239	AbbVie (prior sponsor, Abbott)	Aug 2010
NCT01510548	ADALISKIAS	ADALISKIAS: Adalimumab for Acute Disc Prolapse	P3	unknown	90	Kuopio University Hospital	Mar 2007
NCT01812954		Economic Evaluation of Systemic Treatments for Moderate-to-severe Psoriasis	—	completed	1	Jochen Schmitt.	Mar 2013
NCT00963313		A 24 Week Open Label Study of the Utility of Adalimumab in Active Axial Forms of Psoriatic Arthritis	—	completed	29	Dr. FRANCISCO J. BLANCO-GARCIA	Mar 2010
NCT02045979		Pharmacokinetics and Safety in Healthy Volunteers	P1	completed	327	Boehringer Ingelheim	Jan 2014
NCT01088165	CASTIP	The Influence of Adalimumab on Cardiovascular and Metabolic Risk in Psoriasis	P4	unknown	66	Medical University of Vienna	May 2010
NCT01064856		Study of Adalimumab in Participants With Peripheral Spondyloarthritis (SpA)	P3	completed	165	AbbVie (prior sponsor, Abbott)	Feb 2010
NCT01468233	PIONEER II	Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa	P3	completed	326	AbbVie (prior sponsor, Abbott)	Nov 2011
NCT01899755	PK	A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability, Immunogenicity, and Pharmacodynamics (PD) of GSK2800528 in Healthy Subjects.	P1	completed	45	GlaxoSmithKline	Jul 2013
NCT01562951	ADACAL	Assessment of Mucosal Activity to Improve the Prognosis of Patients With Crohn's Disease Treated With Immunosuppressants	P3	terminated	15	Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa	Oct 2012
NCT01174186	INTASAH	Intestinal Inflammation in Ankylosing Spondylitis and the Effects of Adalimumab on Mucosal Healing	P4	completed	30	Regionshospitalet Silkeborg	Oct 2010
NCT01870986	REFLECTIONS B538-01	Study Of PF-06410293 And Adalimumab In Healthy Subjects (REFLECTIONS B538-01)	P1	completed	210	Pfizer	May 2013
NCT00814255	FONTII	Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial	P2	completed	32	NYU Langone Health	Dec 2008
NCT01338740	ADA-IFX	Switching From Adalimumab to Infliximab	—	completed	21	University Hospital, Ghent	Apr 2011
NCT01468207	PIONEER I	Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa	P3	completed	307	AbbVie (prior sponsor, Abbott)	Nov 2011
NCT00837434		Anti-TNF Agents for the Treatment of Rheumatoid Arthritis	P4	completed	63	National Institute of Allergy and Infectious Diseases (NIAID)	Mar 2009
NCT01646073		Safety and Efficacy Study of Adalimumab in the Treatment of Plaque Psoriasis	P3	completed	425	AbbVie (prior sponsor, Abbott)	Aug 2012
NCT01494857		Efficacy and Safety of Adalimumab for the Induction of Clinical Response in Ulcerative Colitis	P3	unknown	200	Clalit Health Services	Jan 2012
NCT01029847	ASIM	Adalimumab in Axial Spondyloarthritis (ASIM) - MRI and Biomarkers in Patients With Spondyloarthritis	P4	completed	49	Rigshospitalet, Denmark	Dec 2009
NCT01752855		Study in Rheumatoid Arthritis for Subjects Who Completed Preceding Study M13-390 With Adalimumab	P2	completed	88	AbbVie (prior sponsor, Abbott)	Dec 2012
NCT01644396		An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation	P4	completed	50	AbbVie (prior sponsor, Abbott)	May 2012
NCT01233583		Regulatory T-cells in Psoriasis Patients as Targets for Therapy	—	completed	38	University of Aberdeen	Jun 2010
NCT01264770	OSKIRA -4	Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)	P2	terminated	644	AstraZeneca	Jan 2011
NCT00939003		Study of Adalimumab in Patients With Axial Spondyloarthritis	P3	completed	192	AbbVie (prior sponsor, Abbott)	Jul 2009
NCT00853099		A Study of Adalimumab in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis	P3	completed	274	AbbVie (prior sponsor, Abbott)	Feb 2009
NCT01000441	ROC	Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis	P4	completed	300	University Hospital, Strasbourg, France	Dec 2009
NCT01483599	X-PLORE	A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis	P2	completed	293	Janssen Inc.	Nov 2011
NCT01295814		Efficacy Study of Adalimumab to Treat Interstitial Cystitis	P3	completed	43	ICStudy, LLC	Mar 2011
NCT02092961	OSKIRA 4 SS	Randomised Double-Blind, Placebo-Controlled, Parallel Group Study in Patients With Active Rheumatoid Arthritis:Magnetic Resonance Imaging Sub-Study	P2	terminated	198	AstraZeneca	Feb 2011
NCT01382160	AFORA	Serum Concentration of Adalimumab as a Predictive Factor of Clinical Outcomes in Rheumatoid Arthritis (AFORA)	P4	completed	69	University Hospital, Tours	Jan 2011
NCT01029613		Adalimumab in Rheumatoid Arthritis. An Investigation of Wholebody MRI, Conventional MRI, CT and Circulating Biomarkers	—	completed	40	Glostrup University Hospital, Copenhagen	Dec 2009
NCT02132234		Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis	P4	unknown	100	Jagiellonian University	Jun 2013
NCT01243671		A Study of Adalimumab in Japanese Subjects With Intestinal Behçet's Disease	P3	completed	20	AbbVie (prior sponsor, Abbott)	Oct 2010
NCT01712178	RA	A Study in Rheumatoid Arthritis (RA) Patients to Compare Two Formulations of Adalimumab for Pharmacokinetic, Pharmacodynamic and Safety	P2	completed	100	AbbVie (prior sponsor, Abbott)	Jun 2012
NCT01405326	REWARD	REstore Working Ability in RheumatoiD Arthritis	P4	unknown	160	The Rheumatological Center of Helsinki	May 2011
NCT00855608	ADA01	Intravitreal Adalimumab in Refractory Diabetic Retinopathy, Choroidal Neovascularization or Uveitis: A Pilot Study	P1	unknown	15	Rafic Hariri University Hospital	Mar 2009
NCT00775437	JIA	Active Juvenile Idiopathic Arthritis (JIA) Compassionate Use	P3	completed	32	AbbVie (prior sponsor, Abbott)	Mar 2009
NCT00348153		Adalimumab in Uveitis Refractory to Conventional Therapy (ADUR Trial)	P2/P3	unknown	40	Heidelberg University	Aug 2006
NCT01185288	MUSICA	A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)	P4	completed	309	AbbVie (prior sponsor, Abbott)	Sep 2010
NCT00477893	DANISH	Danish Multicenter Study of Adalimumab in Spondyloarthritis	P4	unknown	52	Glostrup University Hospital, Copenhagen	Feb 2006
NCT01060098		T Cells and TNF (Tumor Necrosis Factor): The Impact of TNF Blockade	—	completed	48	Imperial College London	Apr 2010
NCT01561313		Crossover Study of Safety and Tolerability of Two Formulations of Adalimumab.	P2	completed	64	AbbVie (prior sponsor, Abbott)	Mar 2012
NCT01502423		A Crossover Study of the Safety and Tolerability of Two Formulations of Adalimumab	P2	completed	61	AbbVie (prior sponsor, Abbott)	Jan 2012
NCT00929864		Abatacept Versus Adalimumab Head-to-Head	P3	completed	869	Bristol-Myers Squibb	Oct 2009
NCT01185301	CONCERTO	Study to Determine the Effects of Different Doses of Methotrexate (MTX) When Taken With Adalimumab in Subjects With Early Rheumatoid Arthritis (RA)	P3	completed	395	AbbVie (prior sponsor, Abbott)	Oct 2010
NCT00808509	ADMIRE	A Pilot Study of the Feasibility of Discontinuation of Adalimumab in Stable Rheumatoid Arthritis Patients in Clinical Remission	P4	completed	33	AbbVie (prior sponsor, Abbott)	Jan 2009
NCT01283971	MTX	A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor	P4	terminated	96	Hoffmann-La Roche	May 2011
NCT01505491		Pharmacokinetics and Safety Study of BI 695501 in Healthy Subjects	P1	completed	193	Boehringer Ingelheim	Dec 2011
NCT01657513		TNF-alfa Inhibitors and Antibody Production in Patients With Psoriasis	N/A	unknown	60	University Hospital, Gentofte, Copenhagen	Jun 2012
NCT00726804	SPARTA	Discontinuation of TNF-alpha Inhibitors in Patients With Spondyloarthritis	P4	terminated	7	Glostrup University Hospital, Copenhagen	Mar 2008
NCT01275508	FA-Crohn	Safety and Tolerability of FITC-Adalimumab Administration During Confocal Laser Endomicroscopy of the Gut	P1/P2	completed	25	University of Erlangen-Nürnberg Medical School	Jan 2011
NCT00195663	PREMIER	Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis	P3	completed	799	AbbVie (prior sponsor, Abbott)	Dec 2000
NCT01265823		Immediate Response With Adalimumab and Its Impact on Quality of Life and Other Comorbidity Factors in Patients With Moderate to Severe Plaque Psoriasis	P4	completed	150	AbbVie (prior sponsor, Abbott)	Oct 2010
NCT00274352		A Study of Adalimumab to Treat Sarcoidosis of the Skin	P2	completed	16	Pariser, Robert J., M.D.	Sep 2006
NCT01119859		A Study of Tocilizumab (RoActemra/Actemra) Versus Adalimumab in Patients With Rheumatoid Arthritis	P4	completed	326	Hoffmann-La Roche	May 2010
NCT00736983	Adafi	Adalimumab in Combination With Ciprofloxacin/Placebo Treatment of Perianal Fistulas in Crohn's	P3	completed	76	Foundation for Liver Research	Sep 2008
NCT00660647	OPERA	Optimized Treatment Algorithm for Patients With Early Rheumatoid Arthritis (RA)	P3	completed	180	University of Aarhus	Sep 2007
NCT01136252		Intravitreal Adalimumab in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration	P2	completed	5	Hospital Universitari Vall d'Hebron Research Institute	May 2010
NCT01181570		Efficacy and Safety of Adalimumab in Patients With Psoriasis and Obstructive Sleep Apnea	P4	completed	20	Innovaderm Research Inc.	Sep 2010
NCT00690573		Safety, Efficacy, and Pharmacokinetics of Adalimumab in Japanese Children With Juvenile Rheumatoid Arthritis	P3	completed	25	Abbott	May 2008
NCT00940862		Effect of Adalimumab on Vascular Inflammation in Patients With Moderate to Severe Plaque Psoriasis	P4	completed	30	Innovaderm Research Inc.	Jul 2009
NCT00870467		A Study of Adalimumab in Japanese Subjects With Rheumatoid Arthritis	P3	completed	334	Abbott	Mar 2009
NCT00298272		Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis	P2	terminated	54	Biogen	May 2006
NCT01465438	HUPSA	HUmira in Psoriatic Arthritis	P4	completed	42	Glostrup University Hospital, Copenhagen	Nov 2006
NCT00305539	HECTHOR	HECTHOR: Humira to Spare Steroids in Giant Cell Arteritis	P3	completed	69	Assistance Publique - Hôpitaux de Paris	May 2006
NCT00195650		Long Term Open Label Continuation Study	P3	completed	846	Abbott	Jul 2000
NCT02322008		Anti-TNF Therapy in Danish Patients With Inflammatory Bowel Diseases in Clinical Practice	—	completed	1,035	Regionshospitalet Viborg, Skive	Sep 2009
NCT00814866	BROCA	Bone Resorption, Osteoclastogenesis and Adalimumab	N/A	completed	28	Université de Sherbrooke	Sep 2008
NCT00514982		Medical Treatment of Colitis in Patients With Hermansky-Pudlak Syndrome	P2	withdrawn	0	National Institute of Allergy and Infectious Diseases (NIAID)	Aug 2007
NCT01114880		Efficacy and Safety of Adalimumab in Adult Chinese Subjects With Active Ankylosing Spondylitis	P3	completed	344	Abbott	Jan 2010
NCT01270035		Efficacy and Safety of Adalimumab 80 mg Every Other Week With Methotrexate	P4	unknown	40	Keio University	Jan 2011
NCT00667355		A Study of Adalimumab in Japanese Subjects With Active Ankylosing Spondylitis	P3	completed	41	Abbott	Feb 2008
NCT01237262	ELIDACE	Evaluation of Lymphocytic Infiltrate, Dendritic Cells and Cytokines Expression in Psoriatic Lesion and Normal Skin Before and After TNF Alfa Inhibitors Therapy	P4	unknown	20	University of Padova	Nov 2010
NCT01225393	DMARD	A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis	P2	completed	211	Genentech, Inc.	Nov 2010
NCT00918255		Study of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa	P2	completed	154	Abbott	Apr 2009
NCT00686439		Adalimumab for Inflammatory Osteoarthritis	P1/P2	completed	20	University of Alberta	Jun 2008
NCT00445432		A Study of Adalimumab for the Maintenance of Clinical Remission in Japanese Subjects With Crohn's Disease	P2/P3	completed	82	Abbott	Mar 2007
NCT00796705	RA	Switching Anti-TNF-Alpha Agents in Rheumatoid Arthritis (RA)	P4	terminated	13	National Institute of Allergy and Infectious Diseases (NIAID)	Nov 2008
NCT00525902		Adalimumab (Humira) in the Treatment of Refractory Non-infectious Uveitis	P2	completed	31	Oregon Health and Science University	Jan 2008
NCT00195702		Efficacy and Safety of Adalimumab in Patients With Active Rheumatoid Arthritis Treated Concomitantly With Methotrexate.	P3	completed	619	Abbott	Feb 2000
NCT00420927	OPTIMA	Study of the Optimal Protocol for Methotrexate and Adalimumab Combination Therapy in Early Rheumatoid Arthritis	P4	completed	1,032	Abbott	Dec 2006
NCT00234884	ReAlise	Post-marketing Observational Study in Subjects With Rheumatoid Arthritis	—	completed	3,435	Abbott	Sep 2003
NCT00048542	JIA	Study of Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis (JIA)	P3	completed	171	Abbott	Sep 2002
NCT01144156		Small Bowel Mucosal Healing Induced by Adalimumab in Crohn's Disease Patients as Assessed by Capsule Endoscopy	N/A	unknown	30	Rabin Medical Center	—
NCT00409682		Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Crohn's Disease	P3	completed	192	Abbott	Apr 2007
NCT01078571	DALI	Safety and Effectiveness of Adalimumab in Patients Diagnosed With Rheumatoid Arthritis	—	completed	705	Abbott	May 2006
NCT00647400		Adalimumab in Adult Japanese Subjects With Psoriasis	P2/P3	completed	147	Abbott	Apr 2006
NCT00385736		Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Acute Ulcerative Colitis	P3	completed	576	Abbott	Nov 2006
NCT00408629		Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Active Ulcerative Colitis	P3	completed	518	Abbott	Nov 2006
NCT01078610	ELAN	Safety and Effectiveness and Effect on Quality of Life and Work Productivity of Humira in Patients With Psoriatic Arthritis in Clinical Routine	—	withdrawn	0	Abbott	—
NCT01231321		A Study of Adalimumab When Added to Inadequate Standard Anti-rheumatic Therapy in Patients With Active Rheumatoid Arthritis	P3	completed	100	Abbott	Dec 2007
NCT00972218		Effectiveness and Safety of Spondylitis Related to Inflammatory Bowel Disease	P4	withdrawn	0	University of Alberta	Jul 2009
NCT00538902		Safety and Efficacy Study of Adalimumab in Adult Chinese Rheumatoid Arthritis Subjects Treated With Methotrexate	P2/P3	completed	302	Abbott	Aug 2007
NCT00595413	AUGUST II	Atacicept in Anti-Tumor Necrosis Factor Alpha-naïve Subjects With Rheumatoid Arthritis (AUGUST II)	P2	completed	311	EMD Serono	Sep 2007
NCT00195676		Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis	P3	completed	1,469	Abbott	May 2004
NCT00735787		Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet	P4	completed	81	Abbott	Aug 2008
NCT01012570	CD	The Effect of Adalimumab on the Bone Microstructure in Crohn's Disease (CD) Patients	—	terminated	34	Gerhard Rogler	Aug 2009
NCT02252809		Effect of Anti-Inflammatory Agents on Biological Responses to Endotoxin Inhalation in Healthy Subjects	Early P1	completed	51	Brugmann University Hospital	Nov 2008
NCT00724672		A Study of Immune Cells in Patients With Rheumatoid Arthritis During Different Types of Anti-TNF Alpha Treatments (Study P05521)	—	withdrawn	0	Merck Sharp & Dohme LLC	Sep 2008
NCT00085644	ATLAS	Human Anti-tumor Necrosis Factor (TNF) Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis	P3	completed	315	Abbott	Jan 2004
NCT00216177		Comparison of Adalimumab and Infliximab Treatment of Rheumatoid Arthritis	P4	unknown	112	Hvidovre University Hospital	Sep 2005
NCT00195819		Safety and Efficacy of Adalimumab in Patients With Active Ankylosing Spondylitis	P3	completed	82	Abbott	Dec 2003
NCT00566722		Open Label Study of Adalimumab in Subjects Who Have a Sub-optimal Response to Systemic Therapy or Phototherapy	P3	completed	152	Abbott	Jan 2008
NCT00647270		Study Comparing 80 mg of Adalimumab With Placebo, and Demonstrating the Non-inferiority of Monthly 80 mg Adalimumab Dosing Compared With 40 mg Adalimumab Every Other Week Dosing	P3	completed	420	Abbott	Dec 2007
NCT00296894		Study to Evaluate the Efficacy of Adalimumab in Patients With Erosive Osteoarthritis of the Interphalangeal Finger Joints	P2	completed	60	University Hospital, Ghent	May 2006
NCT00550446		A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis	P2	completed	386	Pfizer	Sep 2007
NCT00927069		Safety and Efficacy of Adalimumab in Patients Who Showed an Unsatisfactory Response to Etanercept	P3	completed	85	Innovaderm Research Inc.	Mar 2007
NCT00497614	PETRA	Positron Emission Tomography in Rheumatoid Arthritis With Adalimumab (PETRA)	N/A	completed	8	University Hospital, Tours	May 2006
NCT00234234		Predictors of the Response to Adalimumab in Rheumatoid Arthritis	P4	completed	200	University Hospital, Rouen	Jan 2006
NCT00195715		Long-term Safety and Tolerability Study of Adalimumab in Subjects With Crohn's Disease	P3	completed	777	Abbott	Sep 2004
NCT00055497	CLASSICII	Remission in Subjects With Crohn's Disease, 1 Year Phase	P3	completed	276	Abbott	Aug 2002
NCT01070303	CLASSICII	Remission in Subjects With Crohn's Disease, Open Label Extension	P3	completed	177	Abbott	Aug 2002
NCT00311246		Trial of Adalimumab in Progressive Sarcoidosis	P2	terminated	11	University of Chicago	Apr 2006
NCT00827996	HIDRI2007	To Assess the Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa	P2	completed	10	Florida Academic Dermatology Centers	Feb 2007
NCT00761514	VIVIR	Evaluation of Quality of Life Changes in Puerto Rican Subjects With Active Rheumatoid Arthritis Treated With Humira	P4	terminated	14	Abbott	Nov 2006
NCT00409617		Study of Adalimumab Treatment for Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease	P3	completed	945	Abbott	Dec 2006
NCT00470509	ASAS	Adalimumab in Severe and Acute Sciatica	P2	completed	61	University Hospital, Geneva	May 2005
NCT00690911		Study to Determine the Efficacy of Adalimumab in the Treatment of Cutaneous Sarcoidosis	P2	withdrawn	0	Wake Forest University	—
NCT00421642		Open-Label Adalimumab for Ulcerative Colitis Patients	P1	completed	20	Mayo Clinic	Oct 2006
NCT00650390	PROWD	Open Label Study to Assess Efficacy and Safety of the Fully Human Anti-TNF-Alpha Monoclonal Antibody Adalimumab	—	approved for marketing	0	Abbott	—
NCT00650026	ReAct	Early Access Program of the Safety of Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Rheumatoid Arthritis	—	approved for marketing	0	Abbott	—
NCT00649545	CanAct	Study of the Human Anti-TNF Monoclonal Antibody in Patients With Active Rheumatoid Arthritis	—	approved for marketing	0	Abbott	—
NCT01072058		Heart Function in Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF Blocker	P4	unknown	100	University of Sao Paulo	Feb 2008
NCT00427921	ACCESS	Human Anti-TNF Monoclonal Antibody Adalimumab in Canadian Subjects With Moderate to Severe Crohn's Disease (ACCESS)	P3	completed	304	Abbott	Jan 2007
NCT00574249	BELIEVE	Adalimumab in Combination With Topical Treatment (Calcipotriol/Betamethasone) in Subjects With Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic Treatment	P3	completed	730	Abbott	Nov 2007
NCT00193648	FSGS	Pilot Studies of Novel Therapies to Treat Resistant Focal Segmental Glomerulosclerosis (FSGS)	P1	completed	21	Northwell Health	Jul 2005
NCT00513370	PRIDE	A Canadian Open-Label Access Program to Evaluate Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriasis	P3	completed	203	Abbott	Sep 2007
NCT00512863		A Dose-Finding Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Adalimumab in Subjects With Refractory Asthma	P2	withdrawn	272	Abbott	Aug 2007
NCT00690846		Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum	P2	withdrawn	0	Wake Forest University Health Sciences	Jul 2007
NCT00696059	HURRAH	Humira in Rheumatoid Arthritis - Do Bone Erosions Heal?	P4	completed	52	Hvidovre University Hospital	Aug 2004
NCT00650156		Pharmacokinetic and Safety Study With Adalimumab in Chinese Subjects With Mild Rheumatoid Arthritis	P1	completed	24	AbbVie	Jun 2007
NCT00235105		D2E7-Early AS	P2/P3	unknown	46	Charite University, Berlin, Germany	Mar 2005
NCT00338650	CHOICE	Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE)	P3	completed	1,000	Abbott	Jun 2006
NCT00133315		TNFalfa Blocking Treatment of Spondylarthropathies	P4	completed	50	Hvidovre University Hospital	Sep 2004
NCT00291915		Multicenter Randomized Prospective Trial Comparing Methotrexate Alone or in Combination With Adalimumab in Early Arthritis	P4	unknown	80	Goupe d'Etudes et de Recherche Clinique En Rhumatologie	May 2004
NCT00445939		A Study of Adalimumab for the Induction of Clinical Remission in Japanese Subjects With Crohn's Disease	P2/P3	completed	90	Abbott	Feb 2007
NCT01270087		The Effect of Adalimumab (Humira) on Vascular Abnormalities in Rheumatoid Arthritis. A Pilot Study.	P4	completed	14	Skane University Hospital	May 2005
NCT00348283		Effects of Adalimumab on Mucosal Healing in Subjects With Crohn's Disease Involving the Colon	P3	completed	135	Abbott	Aug 2006
NCT00233571		A Long Term Roll-over Study to Investigate the Efficacy and Safety of Adalimumab Given Long-term to Patients With Rheumatoid Arthritis	P3	completed	796	Abbott	Jun 2000
NCT00427362	ACCLAIM	A Canadian Open-Label Study to Evaluate the Safety and Effectiveness of Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriatic Arthritis (PsA) (ACCLAIM)	P3	completed	127	Abbott	May 2006
NCT00603993		Self-injection of Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis	P3	completed	88	Abbott	Mar 2006
NCT00478660	RHAPSODY	An Open-Label Study to Evaluate the Response to Adalimumab in Patients With Active Ankylosing Spondylitis Who Have Failed Standard Therapy or TNF-Alpha Inhibitors (RHAPSODY)	P3	completed	1,250	Abbott	Feb 2006
NCT00185562		A Pilot Trial of Adalimumab for the Treatment of Osteoarthritis	P2	completed	12	Stanford University	Jun 2005
NCT00338754		Adalimumab in Adult Japanese Subjects With Moderate to Severe Chronic Plaque Psoriasis	P2/P3	completed	160	Abbott	Nov 2005
NCT00647491		A Study of Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis	P2/P3	completed	352	Abbott	Feb 2004
NCT00235820	CHAMPION	Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis	P3	completed	271	Abbott	Jul 2005
NCT00235885	STEREO	Safety and Efficacy Study of Adalimumab in Patients With Active Psoriatic Arthritis (PsA)	P3	completed	445	Abbott	Jul 2005
NCT00233558		Open-Label Steroid Reduction Study of Adalimumab With Methotrexate in Patients With Active Rheumatoid Arthritis	P4	terminated	160	Abbott	Jun 2005
NCT00649922		Assessment of the Effect of Adalimumab on Response to Influenza Virus and Pneumococcal Vaccines in Subjects With Rheumatoid Arthritis	P4	completed	226	Abbott	Oct 2003
NCT00237887		Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis	P3	completed	1,212	Abbott	Dec 2004
NCT00105300		Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease	P3	completed	300	Abbott	Oct 2004
NCT00235872		Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis	P3	completed	309	Abbott	Aug 2004
NCT00234897	HERO	Efficacy of HUMIRA in Subjects With Active Rheumatoid Arthritis	P4	completed	1,938	Abbott	Aug 2004
NCT00234936		Quality of Life Study With Adalimumab in Rheumatoid Arthritis	P3	completed	200	Abbott	Dec 2003
NCT00645892		Extension Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis	P2	completed	32	Abbott	Nov 2003
NCT00195689		Safety and Efficacy of Adalimumab in Patients With Moderate to Severely Active Psoriatic Arthritis	P3	completed	400	Abbott	Aug 2003
NCT00077779	CHARM	Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease	P3	completed	854	Abbott	Jul 2003
NCT00235859		Adalimumab Administered in Korean Rheumatoid Arthritis Subjects Treated With Methotrexate	P3	completed	128	Abbott	Jul 2003
NCT00647920		Study of Adalimumab Administered as Subcutaneous Injections in Adult Chinese Rheumatoid Arthritis Subjects Treated With Methotrexate	P3	completed	47	Abbott	Jul 2003
NCT00645905		Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis	P2	completed	148	Abbott	Jun 2003
NCT00646178		Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severely Active Psoriatic Arthritis Subjects With Inadequate Response to Disease Modifying Anti-Rheumatic Drug Therapy	P3	completed	102	Abbott	Jun 2003
NCT00235833		Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis	P2	completed	25	Abbott	Jun 2003
NCT00646191		Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis	P2	completed	137	Abbott	Mar 2003
NCT00234845		Adalimumab in Combination With Methotrexate vs Methotrexate Alone in Early Rheumatoid Arthritis	P3	completed	148	Abbott	Mar 2003
NCT00646386		Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderately to Severely Active Psoriatic Arthritis	P2	completed	315	Abbott	Mar 2003
NCT00645814		Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis	P2	completed	148	Abbott	Mar 2003
NCT00049751		Study of Human Anti-TNF Monoclonal Antibody D2E7 in Subjects With Active Rheumatoid Arthritis	P3	completed	3,000	Abbott	Sep 2002
NCT00448383	ReAct	A Study to Assess the Safety and Efficacy of Adalimumab When Added to Inadequate Standard Anti-Rheumatic Therapy in Patients With Active Rheumatoid Arthritis	P3	completed	6,610	Abbott	Sep 2002
NCT00055523		A Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease	P2	completed	300	Abbott	Apr 2002

Adalimumab clinical trials: frequently asked questions

How many Adalimumab clinical trials are there?: 463 Adalimumab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 31 are actively recruiting participants. 307 are marked completed.
Are Adalimumab clinical trials recruiting in 2026?: Yes — 31 Adalimumab trials are actively recruiting in 2026, with 66 U.S. sites across 27 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Adalimumab being studied for?: Adalimumab is being studied for Rheumatoid Arthritis, Psoriasis, Crohn's Disease, Ulcerative Colitis, Psoriatic Arthritis and 188 more. The trials are grouped by indication on this page.
What phase is Adalimumab in?: Adalimumab clinical trials span 116 Phase 4, 153 Phase 3, 71 Phase 2, 28 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Adalimumab clinical trials?: The lead sponsor across the most Adalimumab trials is Abbott, with 215 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Adalimumabas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed June 18, 2026.

Related pages on Hipa.ai:

Adalimumab overview Adalimumab evidence & publications